Quo Vadis Oncological Hyperthermia (2020)?

Sun-Young Lee¹, Giammaria Fiorentini², Attila Marcell Szasz³, Gyula Szigeti⁴, Andras Szasz⁵* and Carrie Anne Minnaar⁶

¹ Department of Radiation Oncology, Chonbuk National University Hospital, Jeonbuk, South Korea, ² Medical Oncology Department, Ospedale San Salvatore, Pesaro, Italy, ³ Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary, ⁴ Innovation Center, Semmelweis University, Budapest, Hungary, ⁵ Biotechnics Department, St. Istvan University, Godollo, Hungary, ⁶ Department of Radiation Oncology, Wits Donald Gordon Medical Center, Johannesburg, South Africa

Heating as a medical intervention in cancer treatment is an ancient approach, but effective deep heating techniques are lacking in modern practice. The use of electromagnetic interactions has enabled the development of more reliable local-regional hyperthermia (LRHT) techniques whole-body hyperthermia (WBH) techniques. Contrary to the relatively simple physical-physiological concepts behind hyperthermia, its development was not steady, and it has gone through periods of failures and renewals with mixed views on the benefits of heating seen in the medical community over the decades. In this review we study in detail the various techniques currently available and describe challenges and trends of oncological hyperthermia from a new perspective. Our aim is to describe what we believe to be a new and effective approach to oncologic hyperthermia, and a change in the paradigm of dosing. Physiological limits restrict the application of WBH which has moved toward the mild temperature range, targeting immune support. LRHT does not have a temperature limit in the tumor (which can be burned out in extreme conditions) but a trend has started toward milder temperatures with immune-oriented goals, developing toward immune modulation, and especially toward tumor-specific immune reactions by which LRHT seeks to target the malignancy systemically. The emerging research of bystander and abscopal effects, in both laboratory investigations and clinical applications, has been intensified. Our present review summarizes the methods and results, and discusses the trends of hyperthermia in oncology.

Keywords: hyperthermia, oncology, trend, immune effects, bystander-effect, abscopal effect

INTRODUCTION

Nowadays, oncology is one of the most interdisciplinary research fields, which includes biology, biophysics, biochemistry, genetics, environmental sciences, epidemiology, immunology, microbiology, pathology, physiology, pharmacology, psychology, virology, and more. Moreover, a wide range of diagnostic and treatment methods are available to identify and destroy malignant tissues. The efficacy of treatment regimens often relies on the fine balance between cure and toxicity and a modality with minimal toxicity and rare complications would be a welcome compliment to the treatment arsenal.
HISTORY OF HYPERTHERMIA

Hyperthermia is an ancient physical method and inducing artificial fevers was a common goal for ancient doctors. The development of electromagnetic heating methods in the early 1900s revolutionized the application of heat for therapeutic gains including the treatment of malignancies. In the first quarter of the 19th century, electromagnetism was applied as a healing process. The German Electric Belt Agency went further, advertising that practitioners should reduce or even stop using drugs, applying for treatment by electricity alone. A French doctor, Arsene D’Arsonval, introduced a pure electromagnetic treatment called “Darsonvalization.” The absorbed electromagnetic energy resulted in heating, however the effects of heating were initially neglected. Following early observations those increased temperatures in tumors were associated with improved outcomes, and the goal of the electromagnetic therapies shifted to increasing the temperature of the tumors.

The long history of the use of hyperthermia has not benefited the method, and has increased skeptical opposition as various techniques and protocols have been developed over the years which have displayed varying results from positive to negative. The rapid proliferation of malignant tissue is accompanied by higher biochemical reaction rates in the tumor's metabolic rates. This, in turn, generates heat and results in temperatures which are higher than the surrounding healthy baseline temperatures. The metabolic heat production of the tumor itself depends on the duration of the doubling of its volume. The increase in the chemical reaction rate is demonstrated in the Arrhenius plots which show the reaction change by temperature and this is the basis of the cumulative equivalent minutes (CEM) dosing concept, as described by Urano et al. With a better understanding of the effects of temperatures on tumors, the goal of hyperthermia in oncology shifted to the measurement of the temperature achieved within the treated tumor.

The thermal effect of the electromagnetic energy absorption was much simpler to understand and easier to study. The effects of the temperature approach became more robust when Siemens, one of the largest producers of electromagnetic devices at that time, marketed the “diathermia” devices, which were devoted to the cure of cancer. Thermo-radiation therapy was approved after a controlled phase II clinical trial with 100 patients in 1912, and further successes were reported by Westermark, and Overgaard. Intensive publication activity on the development of the methods and their benefits started in the first half of the 20th century. A further push on the development was the discovery of microwaves, and a practice working similarly to microwave ovens began. Since then, despite many positive developments and proofs, some uncertainties remain.

This positive period for hyperthermia in oncology was followed by one of negative skepticism. In 1964, the leading German surgeon, Bauer, presented doubts about the results in a monograph titled "Das Krebsproblem" (14): “All of these methods impress the patient very much; they do not impress their cancer at all.” His skepticism toward oncological hyperthermia became widespread and common among medical experts, who declared hyperthermia to be of no benefit for cancer patients, and subsequently did not endorse the addition of hyperthermia to therapy protocols. The general policy was to avoid hyperthermia in oncotherapies. Some animal studies even suggested that hyperthermia could increase the dissemination and development of metastases, and the safety of hyperthermia in humans was questioned. The benefits of hyperthermia were however still noted and the investigations began to delve deeper into the methods and protocols.

A vast amount of research and clinical articles, as well as many books, have demonstrated the efficacy and power of hyperthermia in oncology. The clinical outcomes are the best ways to determine the treatment efficacy. As hyperthermia is most often applied in end stage cases or to tumors with known resistance to treatments, the most frequently listed primary outcome is local disease control. However more recent studies have included survival and disease free survival as outcomes. In a review of 38 trials on various tumor locations (including breast, cervix, head and neck, rectum, urinary bladder, esophagus, lung, skin melanoma, choroidal melanoma, and anal canal), Datta et al. reports an overall complete response rate (RR) of 54.9% in the 1761 participants treated with hyperthermia plus radiotherapy, compared to 39.8% in the 1717 participants treated with radiotherapy alone. There is a wide variety of techniques available to heat tumors, and each technique requires specific measures of treatment efficiency and safety control. Each technique therefore requires its own evaluation and quality assurance guidelines and these documents are regularly updated as the field evolves.

Hyperthermia has been introduced within university curriculums, and has been discussed in detail in major textbooks on radiology/radiotherapy and general oncology. Hyperthermia has now become a part of standard cancer care in some countries, although its application is still limited to only a few cancer types and a few types of heat delivery. Numerous clinical advantages of oncological hyperthermia have been presented. The newest results offer again reason for bright optimism, positioning hyperthermia in oncology.

Meta-analyses have been published of the most recent medical literature dealing with oncological hyperthermia showing its benefits and perspectives. A large body of evidence such as this would be sufficient for the inclusion of the more conventionally applied chemotherapy and radiotherapy treatments into routine practice. However, the critical skepticism regarding hyperthermia has not yet vanished. Some of the leading clinical trials have been strongly criticized. It seems that clear evidence is not enough to convince the experts working in oncology. One renowned expert's critique formulates an important general consequence: “The mistakes made by the hyperthermia community may serve as lessons, not to be repeated by investigators in other novel fields of cancer treatment.” We now ask if the community of radiation oncologists ready for clinical hyperthermia? Despite its long history, the state of oncological hyperthermia today is similar to that of therapies in their infancy. Like many
early-stage therapies, it lacks adequate treatment experience and long-range, comprehensive statistics that can help optimize its use for all indications. We are facing the question of what is important for the success of hyperthermia treatments: the temperature or the bio-electric effects, or perhaps both? The search for the explanations of the basic mechanisms of hyperthermia is not yet complete and a new perspective is needed in order to achieve success.

The gold-standard therapies continue to develop intensively: we have seen new radiotherapy techniques (proton and heavy particle therapies, tomotherapy, radiative seeds, etc.), new chemotherapies (antibody therapies, oral medications, check-point inhibitors etc.), and great advances in surgery (minimally invasive surgery, laparoscopic surgery, endoscopic surgery, robotic surgery etc.) in recent years. Unfortunately, oncological hyperthermia has not changed in its thinking regarding the thermal concept that is historically applied. There have been fascinating discoveries in oncotherapies, heading toward immuno-oncology (52); however, the overemphasis on the temperature has remained the leading concept in hyperthermic oncology, ignoring the challenge of the complexity of human medicine (53). In this article we review the technical aspects of various hyperthermia techniques, along with the challenges of the techniques and the advances, and we propose a method of heating tumors which does not require the use of the temperature outcome as a measure of efficiency.

Hyperthermia Methods in Oncology
A surprisingly large number of hyperthermia methods exist in oncotherapies (54). Different heating processes and technical solutions have been developed (Table 1).

WHOLE BODY HYPERTERMIA
Systemic heating, or whole-body hyperthermia (WBH), is induced by high power technical variants (55), but their common goal is to heat up the blood (mainly peripherally) and for the heated blood to heat up the whole body. Direct contact heating (hot water, hot wax, wrapping the body in a heated blanket etc.) is rarely applied, although water-bath-heating using extremely high temperatures has had its “renaissance” (56). These mainly “heat-conductive methods” have a high risk of burning of the skin’s surface. To avoid burning in the uppermost surface, a so-called water-window effect in the infrared region (denoted by IR-A) of electromagnetic waves is used. This spectrum of the infrared region penetrates deep into the subcutaneous layer and directly heats the blood in the capillaries. Technically this spectrum is selected by multi-reflection filtering (57), water-filtering (58), and multilayer reflection filtering (59). There is also a method by which blood is heated using an extracorporeal setup with outside circulation (60). Whole body hyperthermia methods are illustrated in Figure 1.

LOCAL AND REGIONAL HYPERTERMIA
Various techniques are used to achieve local-regional hyperthermia (LRHT), all of which have the end goal of the destruction of the tumor. Techniques that have been developed to achieve this include: infrared water-window (IR-A); (61, 62) Hyperthermic Intraperitoneal Chemotherapy (63, 64), [HIPEC: heating the abdominal organs using a warm chemo solution applied during open surgery (65) or laparoscopic surgery (66)] and High-intensity focused ultrasound [HIFU, for deep non-invasive heating (67, 68)]. Photodynamic therapy (PDT) and its different versions are local energy-absorption applications which use the activation of a photosensitizer by the appropriate light dose (usually using a laser-beam in a minimally invasive way) (69). Nanoparticles (70) and even nanotubes (71) are used for modern PDT purposes. The use of laser energy being absorbed by sensitzer molecules is a form of micro-hyperthermia, which could also be combined with conventional hyperthermia such as interstitial heating (72).

Interstitial heating is an invasive form of local hyperthermia that involves the implantation of arrays of needle-shaped applicators directly into the tumor, or the insertion of applicators within catheters that are implanted into the target volume (37). Non-invasive forms of local hyperthermia include the use of radiofrequency (73, 74) and microwave (75, 76) ablation (RFA and MFA). These techniques assume relatively low energy absorption, but due to the small volume which absorbs this energy, the temperature increases. These emerging technologies are more geared toward minimally invasive surgery and interventionan radiology. The ablative necrosis and radical burning solutions differ from gentler hyperthermia effects in that general hyperthermia avoids burning, and describes burns

**TABLE 1 | Basic categories of hyperthermia in oncology.**

| Active physical effect | Example            |
|------------------------|--------------------|
| Heat delivery          | Conduction, convection, radiation, bioactive |
| Energy source          | Chemical, biological, mechanical, electromagnetic |
| Invasivity             | Non-invasive, semi-invasive, invasive |
as a toxicity or adverse event [hot-spots and adipose burns (fat-necrosis)].

**The Use of Electromagnetic Energy in Hyperthermia**

Energy absorption for heating differs from the ionizing radiation energy delivery method. The used non-ionization electromagnetic effects are sensitive to the bio-electromagnetic heterogeneity of the target volume. The thermal heterogeneity together with the complex feedback mechanisms create challenges as well. The heterogeneity of biological material is complexly regulated by homeostasis. Presently, most of the modern oncotherapies could be combined with hyperthermia (77). Multiple parameters have to be considered in order to optimize the variables of the actual application. The broad range of classifications and technical characteristics of hyperthermia techniques are summarized in Table 2.

Frequency dispersion relates to the refraction of the electromagnetic waves as they pass through different mediums. Different tissues in the body have varying biophysical qualities such as protein, water, and electrolyte content. In the application of hyperthermia using electromagnetic waves, this interaction between the electromagnetic waves and the medium (the body) is one of the main factors influencing the effects of the treatment. This allows for specific and dynamic interactions between the different layers of tissue, each of which varies in the bio-physical qualities. Figure 2 illustrates the dispersion noted at various frequencies in various tissues.

Dispersion is dependent on the frequency of the energy input. Four dispersion regions have been described at four ranges of frequency: alpha-dispersion; beta-dispersion; delta-dispersion; and gamma-dispersion. The dispersion determines which molecules are affected and subsequently undergo phase transition. In the beta-dispersion range, there is an increase in conductivity of around 0.45 S/m, and an increase of 0.5–0.5 S/m is seen in the delta-dispersion range. Beta-dispersion is primarily due to the capacitive charging of the cell membrane, with a small contribution from the dipolar orientation of tissue proteins. This range therefore effects the cell membranes. Delta-dispersion is primarily due to the broader relaxation of water molecules alone. However, if the effects of the free water molecules are subtracted then the effects of delta-dispersion extend into the radio-frequency (RF) range. Delta-dispersion acts on the lipids and proteins within the cell membranes, as a result of several interactions, including the dipolar relaxation of membrane-bound water, and the rotation and relaxation of the of proteins and polar-side chains. The result is a high absorption of electromagnetic energy by the membrane and protein-bound water molecules and an effect on the transmembrane proteins, and membrane rafts. Modulated electro-hyperthermia, at 13.56 MHz, is between the beta- and delta-dispersion ranges, and therefore makes use of both the effects described above, selecting the transmembrane proteins and the membrane-bound and protein-bound water molecules.

The same forwarded energy exposition with identical energy-flow (W/m²) can cause different energy-absorptions depending on the given conditions (78, 79), the actual organ (80), and the actual frequency (81). If the frequency is not correct, the phase transition does not occur and instead the field passes through or around the molecules. In this manner the cell membrane is able to shield the intracellular contents at lower frequencies, but higher frequencies can penetrate the intracellular environment. As molecules absorb the energy, a phase transition may occur. It is therefore possible to target or effect a specific change by choosing the correct frequency input.

The antenna-array coupling is used for energy delivery into the target (82). Its subsequent developments – the annular phase array (83), the matched phase array (84), the Sigma60 (85) and the Sigma-Eye (86) applicators – use a high-frequency RF (60–150 MHz). The antenna array needs a higher frequency which is necessary for the accurate focusing. Unfortunately, these frequencies lie outside the electromagnetic compatibility standards for free frequencies, and therefore require shielding (Faraday-cage). Nevertheless, multiple controlled clinical trials have shown the efficacy of this method (87–89).

An electromagnetic field is an electric and magnetic force field, a property of space, that forms around moving, charged particles. When the charged particles are stationary, causing a difference in the electric potential between two points, voltage is formed between the two points and an electric field forms around the source of the voltage. When the charged particle moves, in other words when there is a flow of current, a magnetic field is also

---

**TABLE 2** | Electromagnetic heating methods, based on the heating characters.

| Division by electromagnetic heat delivery methods | Technical character |
|--------------------------------------------------|---------------------|
| By frequency                                     | Infra, microwave, radiofrequency, low-frequency |
| By radiation/conduction                          | Radiative, conductive, mixture |
| By target distance                               | Far-field, near-field |
| By intensity (SAR)                               | Ablative, active heating, stimulating |
| By wave-phase                                    | Phase-dependent, independent |
| By electrolyte conduction                        | Electrolyte-selective, not selective |

**FIGURE 2** | The various frequencies and the associated dispersion. Frequencies have different excitation mechanisms. The energy absorbed at various frequencies (called dielectric loss), is represented graphically for the α, β, and γ absorption range. The 13.56 MHz, which is the carrier frequency of the mEHT, is shown. The distributions are only approximate and depend on the real conditions and heterogeneity of the material, which absorbs the energy. The overlapping of the β/γ ranges has multiple interactions, the effects of which are used for the excitation of membrane rafts, mainly the water-binding transmembrane proteins with their lipid environment.
formed, proportionate to the speed of the charged particle and perpendicular to the electric field. An electric field can also be produced by alternating magnetic fields, forcing the movement of charged particles. Some ferromagnetic particles release heat when exposed to an alternating magnetic field. Ferromagnetic particle hyperthermia makes use of magnetic particles, such as micro-particles (90) and ferrite rods (91, 92) introduced into the target volume. Ferromagnetic rods (seeds) have also been used for non-oncological ablative therapies (93). The human body is highly penetrable by a magnetic field. The magnetic field in this application is typically formed between two coils with a high current flow placed on either side of the target volume which contains the magnetic nano-particle. Complications associated with this involve the invasiveness of the introduction of the particles into the target volume (94), however one advantage is the potential reduction in the risk of hot spot formation or damage to the healthy tissues. This method is still considered highly experimental with only a few studies in humans (95). Using the same idea, a new “intracellular hyperthermia” method was developed (96); however, the efficacy of this treatment is still debated (97). The use of nano-particle magnetic suspensions (98) is an emerging magnet-field application. Other types of magnetic heating can be achieved without the inclusion of extra magnetic material into the tumor, and using only the induction of Eddy-currents (99–101). Although the magnetic field goes through the body, the electric field does not, and the method has a low heating efficacy. Due to problems in the selective targeting of the tumor this method is less popular.

Applications making use of capacitive and the radiative (microwave) solutions have the highest popularity in technical realization; however due to the sharp decrease of penetration depth with the increase of frequency, microwave solutions are mostly applied for surface lesions. The capacitive coupling of energy delivery has become the most frequently applied technique. This coupling has two categories, depending on the matching to patients: plane-wave radiation and resonant impedance matching (favoring the highest available RF-current).

Capacitive coupling has less contraindications than other electromagnetic solutions, due to its simple arrangement, and so sensitive tumors such as those of the lung and the brain can be treated by this technique. The efficacy of capacitive coupling has been verified and validated in the relevant literature (102–104). The RF for the capacitive solution is typically in the 5–30 MHz radiofrequency range, and the preference is mostly for the so-called “free-frequencies” (13.56 MHz, as well as at half and double that frequency). These free frequencies are approved for industrial, scientific and medical use (ISM frequencies) (105).

Modulated electro-hyperthermia applies capacitive coupling with impedance matching in order to maximize the absorbed energy and minimize the reflected, or lost energy (106). Due to the high efficacy of current matching (107), the absorbed energy can be used as the dose control (108, 109) instead of the temperature achieved within the tumor.

Various bio-electromagnetic interactions occur based on the frequency of the field and the coupling strength of the fields to the target (Figure 3). Galvanic coupling typically provides the strongest (most effective for energy delivery) interaction. However applying other coupling methods, such as capacitive coupling, with impedance matching could improve the efficacy by minimizing energy losses and enhancing resonant energy-absorption, thus exceeding the strength of the galvanic coupling.

Electromagnetic loco-regional hyperthermia is a large branch including various methods, but two basic principles are distinguishable: isothermal and non-isothermal heating (Figure 4). The isothermal approach aims to heat up the tumor equally, as homogeneously as possible. Two basic

![FIGURE 3](https://www.frontiersin.org/)

**FIGURE 3** The interaction strengths of the bio-electromagnetic interactions. The “strength” refers to the ability of the energy to be absorbed by the living system.
FIGURE 4 | Basic division of loco-regional hyperthermia categories (112). There are technical solutions in each categories, and each product has its own unique technical details, but all have the end goal to heat, either resulting in either temperature homogeneity or heterogeneity.

technical solutions are used for isothermal (homogeneous) heating: the radiative and the capacitive methods, as depicted in Figure 4. Non-isothermal hyperthermia heats up the tumor non-homogeneously, by selecting characteristics unique to the target volume. The inhomogeneous characteristics of the tumor are heated, but the temperature of the tumor as a whole is not necessarily evenly distributed. Two techniques are applied to achieve non-isothermal heating: particle heating, which uses particles injected into the target volume; and modulated electro-hyperthermia (mEHT) (110), which exploits the selective absorption of energy by glycolipoprotein lipid micro-domains (membrane rafts) (31).

Microwave heating revolutionized local hyperthermia in the 1950s, when the promise of deep heating by focusing on the tumor inside the body was highly attractive and ignited numerous projects. While the dose of the microwave heating in the oven is measured by the applied power and duration of the radiation, hyperthermia for humans could not follow this measure. Isothermal heating involves trying to achieve the best temperature homogeneity of the target. The heating efficacy is uncontrollable in the medical applications due to two reasons:

1. The physiological effects control the thermal homeostasis, the transport of the electrolytes (like blood, lymph, extracellular matrix) appear as a heat-sink of the absorbed energy and create massive thermal inhomogeneity in the non-homogeneous tumor-mass.
2. The presently available techniques are insufficient for focused isothermal deep heating. The variations of the thermal qualities within the targeted volume are non-linearly enhanced by the absorbed energy.

Regardless of the difficulties, the absorbed energy in the targeted body part is estimated based on the achieved temperature, and temperature became the basis of the dose-determination. Furthermore, due to the synergy between hyperthermia and other highly temperature dependent treatment techniques, the primary focus was to enhance the temperature.

Nevertheless, the measurability of the achieved temperature does not consider the thermal heterogeneity of the target. The dose predicts the percentage of isothermal volumes of the target. However, the enormous micro-heterogeneity of the tumor mass due to the intensive and non-linearly regulated blood flow does not allow the real mapping of the temperature in the targeted volume.

EFFECTS OF HYPERTHERMIA

The effects of increased temperatures on cells have been described in detail in the literature over the last four decades (33, 111–114). Despite the plethora of pre-clinical research, the exact mechanisms of some of the effects of hyperthermia remains uncertain. In vitro, temperatures in excess of 41°C inhibit the DNA double strand break repair mechanisms by slowing down the synthesis and function of proteins. The dependence of this action on temperature in vivo is however not yet clear.

Mild temperatures have demonstrated immune-modulating potential and the induction of systemic anti-tumor immune responses (115). Local irradiation combined with combined mild hyperthermia may result in systemic effects through immune mediated abscopal effects (116–118). Temperatures in excess of 43°C can result in the direct destruction of cells, via necrosis, rather that the synergistic action milder temperature's with
chemo-/radiotherapy. Necrosis at these temperatures is primarily achieved by the denaturation of proteins, which are essential to the maintenance of a healthy cell cycle.

Hyperthermia has the added effect of sensitizing cells which are in the S-phase of cell division, a phase during which cells are more likely to be resistant to conventional therapies (33). Hyperthermia with bio-electromagnetic selection targets the tumor and complements the effects of chemo- and radiotherapies due to the chemo-action being mainly in the S-phase of the cell’s cycle (119), while the ionizing radiation is most active in the G1 and mitotic (M) phases. For chemotherapy this support is effective when the chemo-action misses the S-phase [as with Mitomycin (acts in the G1 phase), taxan-derivatives (act in the M-phase) or Epirubicin (acts in the G2 phase)].

The robust synergy between chemotherapy and heat is attributed to the thermally increased metabolism (enhanced chemo-metabolism) and the increased absorption of cytotoxins (120, 121) and cellular chemo-penetration which is promoted by non-equilibrium heat-flows (electro-osmosis) (122). An increase in temperature accelerates the pharmacokinetics (improves the reaction rates). This effect could also be complemented by the temperature sensing of the actual drug (5). Thermo-chemotherapy results in a more efficient therapeutic effect increasing the target specificity and reducing the systemic side effects (123). In some cases, lower-dose chemotherapy could be used (124–126) with hyperthermic promotion. Such optimized chemo-intake helps to overcome the failing of chemotherapies due to patient intolerance (when they are not allowed to take large doses of drugs – for example, due to renal or liver insufficiency or insufficient blood composition). In these cases, the same results may be achieved by combining a decreased chemo dose and heat-therapy (127).

Other advantages of increased temperature include alterations in the cellular membrane, by softening or melting the lipid bilayer (128, 129), and changes in lipid-protein interactions (130). Heat-treatment causes a structural alteration in transmembrane proteins, causing a change in active membrane transport and membrane capacity (131), leading to substantial changes in potassium, calcium, and sodium ion gradients (132), membrane potential (133, 134), and cellular function (135, 136). Hyperthermia increases biochemical reaction rates and, therefore, the metabolic rate. The anaerobic metabolism quickly impoverishes the ATP sources and produces lactate (137), causing hypoxia. The ATP depletion increases ionic imbalance in cells further (138). Another benefit to hyperthermia treatments is the management of pain (139).

### Perfusion

The major factor in homeostatic control is blood circulation. Hence, as a consequence of the increased temperature, multiple factors need to be modified to make this addition to cancer treatment a success. Temperature increases of +2°C above the normal range result in vasodilation (140, 141), while temperatures in excess of 43°C result in vasoconstriction (140). Vasodilation promotes blood and oxygen perfusion which in turn increases the delivery of chemotherapy and enhances the cell killing effects of chemotherapy and ionizing radiation. The increased cell killing effects from ionizing radiation are primarily (but not exclusively) due to an increase in the PO2 in tumors (142), and the increased cell killing effects of chemotherapy is due to a combination of increased drug delivery, increased metabolic rates of the heated cells, and the synergistic effects with the various actions of the drugs on the cell cycle.

The most active regions of a tumor and regions far from the blood supply are usually severely hypoxic; therefore, radiation has reduced efficacy in these areas. The possible vasodilatation caused by hyperthermia aids the synergy by increasing the overall blood perfusion (oxygenation) (143), creating a considerable sensitization to ionizing radiation. This approach was one of the first of the modern hyperthermic effects to be studied, and its characterization was introduced by the thermal enhancement ratio (TER) (144), measuring the efficacy of the treatment. Improving the efficacy of radiotherapy may allow for the possibility to apply a reduced therapeutic dose of radiotherapy, promoted by hyperthermia using the complex TER factor (145, 146). Various review articles have summarized the sensitizing of the classical ionizing radiation by hyperthermia (145, 147–150).

The vascular response to the growing temperature, and the effect of this response on the heating of the tumor, is a complex phenomenon. It has been shown that an increase in temperature can cause vasoconstriction in certain tumors leading to decreased blood perfusion and heat conduction (151–153) in the neo-vascularized area. The tumor's blood flow depends on the tumor's weight as a negative logarithmic function (140, 154), which is a further modifying factor dependent on the development of the tumor's mass; a more developed tumor has less blood flow because of vasoconstriction. So, the blood perfusion of a larger tumor relative to the surrounding healthy tissue is always lower (155) providing an effective heat trap (156, 157), due to the epithelium of new vessels differing from the normal vessels (158). In small tumors and also in the surrounding healthy tissues, the temperature growth causes vasodilatation, which increases the heat conduction in this region (159, 160). The development of blood flow differs in healthy and malignant areas in small tumors too (147).

The mechanisms of physiological regulation and the role of blood flow was not fully understood during the times when hyperthermia in oncology was being developed. The homeostatic regulation devoted to maintaining thermal homeostasis induces a vascular response (140, 154) which increases the blood flow in the heated area, where the fresh blood is a cooling medium. The heated local target is cooled by the blood non-linearly. While the thermal homeostatic control tries to cool down the heated volume, the healthy tissues show vasodilatation. The increased blood flow delivers not only more drug and oxygen, but also supports the tumor-growth with extra nutrients – mainly glucose. This initiates an uncontrolled competition between the thermal damage and the transport support. Furthermore the healthy region induces higher flow than the tumorous (159), and the flow-gradient supports the invasion and dissemination of the malignant cells, which increases the risk of metastases (161). Increased blood flow may therefore pose a risk by supporting...
selected particles and those heat up the tumor where they are target from outside, while the heterogenic heating heats only the tumor. The homogeneous heating method heats all parts of the target volume, or particles which already exist within the tumor. The absorbed energy is the measured parameter. The particles in this method may be foreign magnetic particles introduced into the tumor or microscopic (cellular) selection does not have such a limit. The applied electromagnetic field targets particles and these particles can be supposed to have equal absorbed energy-doses, so here the absorbed energy is the measured parameter. The particles in this method may be foreign magnetic particles introduced into the target volume, or particles which already exist within the tumor. The homogeneous heating method heats all parts of the target from outside, while the heterogenic heating heats only the selected particles and those heat up the tumor where they are located (Figure 5). The selected particles are heated up intensively to have a higher temperature than their environment. To obtain thermal equilibrium the heat moves naturally from the heated target particles to the environment and in doing so heats up the complete target.

The conventional homogeneous heating process has been the subject of a number of reviews. The most recent books about the physics (30) and biology of the process, from research to clinical use (162), show detailed and comprehensive insights into the topic. The use of nanoparticle heating is heterogenic in that the target volume is not heated equally but rather only the targeted particles are heated. However the outcome is a homogenous distribution of the heat as the system moves to re-establish thermal equilibrium. Considering only the outcome and not the method, some reports continue to describe nanoparticle heating as homogenous.

The homogenous principle is applied in radiotherapy treatment planning when the target volume for delivery of conformal dose of radiation is delineated based on the previously measured patient data. Treatment planning is completed independently of the patient’s actual status, movements, changes, and demands at the precise time of irradiation. Sophisticated techniques have been developed to adapt the treatment to the margins as they change with fine movements, such as breathing, during the treatment and with the subtle fluctuations in the patient’s composition between treatment fractions. In homogenous hyperthermia, the development of equally sophisticated techniques to delineate margins and spare the surrounding healthy tissues are necessary. Applying a heterogenic principle however, the need to delineate margins and to treat the complete tumor is reduced, as only the targeted nanoparticles (introduced or naturally occurring), are treated. This enables a self-focusing and continuously adaptive treatment. The target forms part of a resonant electrical circuit which in situ and in real time retunes to any changes or movements, keeping the full system in a controlled synchrony, as illustrated in Figure 6.

Efforts to Reduce the Energy-Loss

While the WBH technology uses the absorbed energy in the body and tries to keep it in the body without losses, the LRHT methods work differently. To heat up a deeply situated target, which is cooled down by the intensified blood flow in a controlled non-linear physiologic loop, LRHT needs a high intensity energy flux on the surface over the target. All the LRHT coupling methods need surface cooling to avoid the overheating of the skin causing thermal toxicity such as epidermal or subcutaneous burns. This cooling helps improve the safety of these methods, but causes two consequences which require consideration (Figure 7):

- The uncontrolled energy which is taken by the cooling process will be missing from the amount supplied. Due to the lost portion of the energy being unknown, the overall energy supplied cannot be used as a treatment dose parameter, the energy balance of the penetration loses its trustworthiness.
- The physiological regulation of blood flow makes the situation complicated (163). The cooled surface will experience vasocontraction, and this layer will become more insulative, as a normal physiological reaction, limiting heat loss. This extra isolation means a higher voltage.
becomes necessary to push through the electromagnetic energy, which decreases the current in the fixed power conditions. The higher voltage has more risk of causing surface burns of the electrical kind, so the surface needs more cooling and the process enters a positive feedback loop. The cooling destabilizes the dynamic equilibrium, decreasing the electric current intensity, which is the main factor upon which the expected heating effect depends.

The capacitive coupling methods (including impedance coupled mEHT) have the further challenge of the distribution of the electric field in the body. It is a crucial point, as the electric field generates the necessary heat-production and the excitement of the molecules by their absorption of energy. Alternating the charge of two symmetrical applicators (electrodes) between positive and negative causes the plane in the middle of the plan-parallel electrodes to have a zero potential. This is due to the canceling effect of the two opposite fields generated by the opposite potentials of the electrode-plates. When one of the electrodes is larger, the symmetry is disturbed and the zero potential plane shifts toward the smaller electrode. When one of the electrodes is grounded, a zero field is created at the point of the grounded electrode, and the field is mirrored, which we can treat as if it were two mirrored patients with one of the electrodes grounded (Figure 8). Both of these solutions have particularities.

The electric potential is zero at the midway point between two equal but opposite charges. Alternating two identical (symmetrical) but oppositely charged electrodes will create the same effect: a plane of zero potential midway between the electrodes. This “virtual zero” point between the symmetrically alternating potentials on the electrodes is very sensitive to the actual symmetry of the target as well as the symmetry of the electrodes. In this technique the tumor should not be in the center, but should be closer to one of the electrodes (ideally the small electrode). This symmetry is not only geometrical but is also considered as symmetrical in its distribution throughout the body, regardless of the non-homogenous quality of the body. The non-homogenous biophysical characteristics of various tissues within the body (for example the bone, adipose tissue and muscles), cause a variation in the response of various tissues to the field. The variations in the biophysical properties (such as conductivity and impedance) are caused by variations in the concentrations of proteins, electrolytes, and water, as well as other factors. The body itself is not symmetrical and the field is
outcomes (177), and a randomized controlled trial on bone HIV positive and negative participants has shown improved controlled trial on mEHT with/without chemoradiotherapy in In the five years since the review, a phase III randomized and III hyperthermia trials which had been published by 2015. excellent summary of the clinical outcomes of the phase II of the scope of this article, however Datta et al. provides an sarcomas (176), and melanomas. A clinical review is outside the head and neck (173), breast (47), cervix (174, 175), demonstrating improved local control and survival, were in cases hyperthermia may improve the efficacy of low-dose chemotherapies (5). Thermo-chemotherapy results in a complementary application of hyperthermia with radiotherapy could be applied in combination with hyperthermia (145, 147, 169). Hyperthermia supports the application of complementary chemotherapies by the increased chemical reaction rate, which grows exponentially with the temperature (109, 170–172). The variety of thermo-chemotherapy and thermo-radio-chemotherapy combinations available offers greater local control of the tumor with less side effects. The temperature sensitivity of the drugs applied supports the complementary application of hyperthermia with chemotherapies (5). Thermo-chemotherapy results in a better therapeutic effect and increases the target specificity as well as reducing the systemic side effects (89, 124). In some cases hyperthermia may improve the efficacy of low-dose chemotherapy (125, 127).

The most well-known phase III randomized controlled trials demonstrating improved local control and survival, were in the head and neck (173), breast (47), cervix (174, 175), sarcomas (176), and melanomas. A clinical review is outside of the scope of this article, however Datta et al. provides an excellent summary of the clinical outcomes of the phase II and III hyperthermia trials which had been published by 2015. In the five years since the review, a phase III randomized controlled trial on mEHT with/without chemoradiotherapy in HIV positive and negative participants has shown improved outcomes (177), and a randomized controlled trial on bone metastases treated with radiotherapy with/without hyperthermia showed a significant reduction in pain and improved palliation (178). A ten year survival report of sarcoma patients treated with chemotherapy with/without hyperthermia showed significantly improved survival rates (179). Two retrospective studies, one of which was a multicenter, double armed study, showed an improvement in survival and disease stabilization of recurrent and resistant brain (180) and pancreatic tumors (181) treated with mEHT versus best supportive care.

### Cervix
One of the most investigated localizations of hyperthermia therapy is for the uterine cervix. Its combination with chemotherapy (Cisplatin + hyperthermia for previously radiated cases) also shows feasibility (182, 183), as well as the combination with radiation (184–186) showing great success. However new evidence (176) fueled the debate with counterpoints (187), counterarguments (188, 189), further debates (190), and responses thereto (191). Some further bimodal (192, 193) and trimodal applications for the cervix (194–196) were also reported regarding locally advanced disease. Conventional and network meta-analyses were conducted for locally advanced evidence-based clinical results which showed the definite efficacy of hyperthermia (46, 48). The outcomes of radiation therapy with radiative hyperthermia or with chemotherapy are comparable (197). The mEHT method was effective in advanced cervical tumors (184), and it has been shown in a Phase III trial that the benefits extend to distant metastases when cervix tumors are treated locally with mEHT and radiotherapy (198).

### Brain
Such sensitive tumors as gliomas are complicated to treat with hyperthermia. The increase of the brain temperature could increase the intracranial edema and intracranial pressure, which could be fatal. However, due to the absence of effective traditional therapies, a relatively high interest in studying heat-effects on the brain is present (199, 200). Due to the risk of increasing intracranial pressure, the precise localization of the incident energy and the precise selection is essential. Numerous, very local, invasive (ablative, interstitial) hyperthermia treatments combined with local irradiation (201–210), in combination with laser techniques (211, 212), implant applications (174, 213), and nano-particle magnetic heating (214) have been applied for the

---

**FIGURE 8** A representation of the effects of two electrodes with opposite charges. (A) Two opposite charges, (B) two plan-parallel electrodes in a capacitive coupling forming a virtual zero field in the center between each electrode, (C) a one-side grounded capacitor, with one electrode and the bed base acting as the second, grounded capacitor, as applied in the impedance matched coupling technique.
treatment of gliomas. A postoperative application has also been published (215). The combination of interstitial hyperthermia with external radiation has also been tried (216). One of these, interstitial (minimally invasive) hyperthermia, was applied in a randomized, controlled double armed (with and without hyperthermia) clinical study (217). It showed a surprisingly good efficacy for brain-gliomas: the median survival period grew from 76 to 85 weeks, and the 2-year survival period was up to 31 from 15%. Subsequently the FDA certified brain-interstitial hyperthermia. Some radiofrequency hyperthermia techniques have been applied intra- and extra-cranially (175, 218, 219), as well as ultrasound hyperthermia (220). It has also been shown that the electric capacitive coupling (called Electric Capacitive Transference) could be effective when applied transcranially (221). The non-invasive electric field application (tumor-treating fields, TTF), without an observable increase of temperature, had remarkably good results, proven by Phase III clinical trial (222), and was approved by the FDA. Modulated electro-hyperthermia has also been applied for gliomas without notable side effects (177, 223–226). Immuno-addition increases the efficacy of mEHT (227), and the economics are also better in this application (228).

Pancreas
A vast proportion of pancreatic tumors are inoperable and only a few options are available for curative treatments. One of the earliest extended therapies studied for the pancreas (229) was with n = 77 patients with resectable and non-resectable adenocarcinoma. The method was capacitive coupling at 13.56 MHz as an immune stimulator. The patients who received hyperthermia got a lower chemotherapy dose. The two groups were compared: with and without the addition of selective immune stimulation. The first-year survival percentages and the median survival period are collected in Table 3. For comparison, three studies of chemotherapies without hyperthermia (230–232) gave 25, 22, and 28% 1-year survival ratios and 6, 7, and 6.5 months median survival periods, respectively.

The minimally invasive ablative hyperthermia technique has also been successfully applied for unresectable pancreatic carcinomas (233), and the feasibility of the treatment of pancreatic cancer with hyperthermia is shown by a meta-analysis (234). Successful clinical trials have shown the advantages of the mEHT method (235–237), applicable also when conventional therapies fail (238).

Breast
Breast cancer is also frequently and successfully treated with hyperthermia in combination with radiotherapy, showing significant advantages compared to radiotherapy alone (239–241). Results of five controlled clinical trials were collected showing the feasibility of hyperthermia in chest wall recurrences in breast cancer (242). Capacitive coupled hyperthermia in combination with radiotherapy has been compared to radiotherapy alone (243) in recurrent and advanced cases (244). It is shown (245) that when the tumor is larger, the local response is better, the gain in the efficacy compared to radiotherapy alone is 13.7% when the tumor is smaller than 100 cm$^3$, and 22.6% when it is larger than 100 cm$^3$. The 4-years overall gain in survival period is almost four times higher (246) with chemotherapy (liposomal doxorubicin) (246), and with trimodal therapy (247). A benefit has also been observed in non-inflammatory cases (248). The ablation technique has also been applied with success (249). A meta-analysis was performed (45) to show the present status of hyperthermia in the therapy of breast cancer. The mEHT method is also applied with success in various advanced cases (250–252), and a randomized clinical trial is expected for complete proof.

Lung
Some successful clinical trials in combination with radiotherapy have shown the feasibility of the hyperthermia method for non-small-cell lung carcinoma (NSCLC). Most of these are combined with radiotherapy, having 14–70 Gy dose in the given cycle. The measured RR was surprisingly high RR = 75%, [n = 12 (253)], and RR = 100% [n = 13 (180)].

A study of advanced NSCLC patients (n = 13, capacitive coupling, f = 8 MHz) to control the local chest invasion (254) showed similarly good results, and the pain-relief was also surprisingly good. Locally advanced NSCLC patients were studied (n = 32) with fractional radiation (180–300 cGy/fraction, 5 fraction/week, median dose 5.58 Gy) (255). Results indicate differences, but they were not significant. The 13.5 month median survival period of the historical control was increased by postoperative (lobectomy or pneumonectomy) application of intrathoracic chemo-thermo therapy (bolus intrathoracic infusion of cisplatin followed immediately by hyperthermia), to 17.5 months, by capacitive coupled hyperthermia (256, 257). The postoperative application of hyperthermia has also been successful in other studies (258). The results of another clinical study (n = 80) on NSCLC shows no significant differences between the active (hyperthermia plus radiotherapy) and control (radiotherapy alone) arms (259) in the local RR but the local progression-free survival period was significantly better (p = 0.036) in the hyperthermia arm, although the number of metastases also increased.

The combination with chemo-thermo therapy has also been investigated for NSCLC with success. In preclinical trials Cisplatin was shown to be effective (260), so clinical studies have

### Table 3 | First-year survival percentages and MST of pancreas hyperthermia treatments (capacitive, 13.56 MHz).

| Additive therapy | All | Far-advanced diseased (%) | No response on conventional (%) | Operated (bypass or resected) (%) | Median survival time (MST) (m) |
|------------------|-----|---------------------------|--------------------------------|----------------------------------|-------------------------------|
| Immune stimulation | 35  | 13.3                      | 34.1                           | 48.7                             | 8                             |
| No immune stimulation | 6   | 0                         | 0                               | 11.1                             | 6                             |
concentrated on this drug and its combinations. The synergy between Gemcitabine and hyperthermia in NSCLC was shown in vitro, and in vivo on nude-mice xenograft model (261). The decrease of the tumor-size and a significant inhibitory effect on growth were shown, and the hyperthermia support of the Gemcitabine induced apoptosis was also demonstrated.

Whole-body hyperthermia has been applied for advanced lung cancer (262). This study (n = 49) showed an effective benefit of hyperthermia, which was more effective in elderly (>60 year) patients. The remission rate was 50%, and the median survival time (MST) was 7 months (mean was 12.7 months) in primary and 5.5 months for metastatic diseases.

Percutaneous ablation with radiofrequency (181, 263) and with laser induced interstitial thermotherapy (264), are also in use for pulmonary tumors. The intrapleural hyperthermia by perfusion is also in use in clinical practice (265). A more experimental technique that appears feasible involves filling the lungs with non-toxic, breathable perfluorochemical (PFC), and subsequently heating the region (266).

The mEHT treatment has successful clinical records on lung cancer (267), and case reports of advanced and special cases support its application (268, 269). When mEHT was applied to lung tumors simultaneously with intravenous ascorbic acid the plasma concentration of ascorbic acid was significantly increased, compared to intravenous ascorbic acid applied alone, or after mEHT. This suggests that mEHT enhances the pharmacokinetic parameters as well (270). An important development is the good results on small-cell lung cancer (SCLC) (271), which opens new perspectives for mEHT in this field.

Liver
The liver is one of the most problematic organs for cancer, because of the poor prognosis of primary hepatocellular carcinoma (HCC) and the frequent liver metastases from a large variety of other localizations. The liver can be successfully treated by local chemotherapy (chemoembolization), which is one of the most popular and successful chemo treatments. Hyperthermia is an excellent synergetic completion of chemoembolization, increasing the remission rate by more than 12% (272). The result is remarkable for larger size tumors. Others have supported these results (273, 274). Hyperthermia works in synergy with numerous different therapies, and all have achieved good results in HCC and also in non-HCC studies (275). Hyperthermia with chemoembolization has been successfully applied for melanoma metastases in the liver (276). Other studies (277–279), have shown excellent complementary results for metastatic liver tumors. Hyperthermia is successfully applied in combination with radiotherapy for non-resectable cases (280), and various ablative techniques have been applied to eliminate liver tumors. Ablation can be done by laser (281), laser in combination with chemoembolization (282) or with the RF ablation technique (283). The application of mEHT has been investigated for the treatment of liver metastases from colorectal cancer and the median survival period in the patients treated with mEHT, with or without chemotherapy (5-FU + FA + MMC) of colorectal metastasis more than doubled (284, 285) and the disease was stabilized (286).

Colorectal
In a study on radiotherapy combined with capacitive hyperthermia for recurrent or non-resectable colorectal tumors only two cases showed progressive disease (287). Similar results were obtained in other studies (288–290) as well. Success could be obtained by applying hyperthermia together with chemotherapy in the case of pre-irradiated lesions (291). Preoperative hyperthermia applications were also successful in the trimodal (chemotherapy, radiotherapy, and hyperthermia combination) approach (292–294), and even intraoperatively (295). Peritoneal carcinomatosis has also been treated successfully with hyperthermia (296, 297).

Esophageal
Good results are obtained for esophageal carcinoma treatment by capacitively coupled (intraluminal 13.56 MHz) hyperthermia (298, 299). A histopathology examination revealed the treatment effect of each type of preoperative adjuvant therapy. The effective rate was 68.8% in the hyperthermo-chemoradiotherapy (HCR) group and 44.1% in the chemoradiotherapy (CR) group (p < 0.05). The survival rates were 50.4% in the HCR group and 24.2% in the CR group. Results were shown in comparison with other studies (300, 301). The treatment efficacy shows a difference in comparison with and without hyperthermia, and could also feasibly be applied preoperatively (302). Results have shown benefits to the use of hyperthermia in combination with radiotherapy for the treatment of recurrent esophagus carcinoma (303) and also when combined with chemo-radio-therapy (299, 304–307).

Head and Neck
The results of capacitively coupled hyperthermia in head and neck carcinoma have also shown definite advantages (308). Curative resection after locally applied radiotherapy with hyperthermia is also feasible (309). An important result for radiotherapy combined with hyperthermia is the observation that the hyperthermia synergy is much higher in the advanced stages than in early-stage cases (310). A randomized study (311) and a summary of clinical studies (312) show improved outcomes when radiotherapy is combined with hyperthermia, including improved 5 year survival rates (313). Improved outcomes have also been demonstrated with the addition of hyperthermia to chemoradiotherapy (cisplatin) (314). A meta-analysis of six clinical trials including 452 participants reported an odds ratio of 2.92 (95% CI: 1.58–5.42, p = 0.001) for local control in favor of hyperthermia combined with radiotherapy versus radiotherapy alone (178).

Gastric
The efficacy of intraperitoneal chemo-hyperthermia for gastric cancer patients with peritoneal carcinomatosis was better for the hyperthermia group, but the results were not significant (315). The radiotherapy combined treatments have been effective in most of the trials (316). Both preoperative (317) and postoperative (318) treatments have been successfully applied, along with hyperthermia combined with radiotherapy (318), chemotherapy (317, 319), and chemoradiotherapy (320).
Peritoneal carcinomatosis and pelvic and abdominal tumors have also been successfully treated by hyperthermia in combination with radiotherapy (321, 322) as well as in combination with the platinum derivative Oxaliplatin (323–325) and also with Oxaliplatin + Irinotecan (326). A meta-analysis shows the feasibility of the method (47). Intraperitoneal chemoinfusion in the treatment of peritoneal carcinomatosis with malignant ascites had been treated (327), showing better results than the conventional therapy.

Superficial Tumors
Superficial tumors have been treated with hyperthermia with great success, mainly in combination with radiotherapy (246). The advantages can be seen well on the local control and local response-rate for melanoma (328–333), as well as for other superficial tumors (334–338).

Bladder
Hyperthermia can be applied for the urinary bladder (339). Survival periods are much longer (over 60% longer) when it's applied with radiotherapy rather than with radiotherapy alone (340). It has also shown its efficacy in high-risk cases in combination with chemotherapy (341). Good results were achieved by hyperthermia plus Mitomycin-C in a randomized trial (342).

Soft Tissue
Hyperthermia has excellent results for soft tissue malignancies (343), especially sarcomas (89, 344, 345). The overall survival period in a long follow-up (over 10 years) was over 85% (346). Hyperthermia could be applied preoperatively (347, 348) and intraoperatively (349), and its whole-body application together with combined chemotherapies (Ifosfamide, Carboplatin, and Etoposide) is also published (350–353). Extensive research and clinical investigation was done on the topic by Issels and his group (347, 354–361). The research culminated in a large (n = 341) phase III randomized controlled trial (362) showing a 29.2% risk reduction (after 5.7 years median follow-up) in local progression or death when lesions were treated with loco-regional hyperthermia combined with surgery and radiotherapy. Some characteristic case reports (363) and a phase II clinical trial were also published with mEHT (364).

Experimental Applications
The combination of hyperthermia with gene therapy also looks promising, as shown by the successful combination of hyperthermia and heat-shock-protein (HSP) promoter-mediated gene therapy in advanced breast cancer patients (365). Hyperthermia improved the results of the HSP-promoter gene therapy by inducing local HSP production and by enhancing the local rate of release of HSPs from liposomes (366); this is also helpful for the double suicide gene transfer into prostate carcinoma cells (367). It was shown that this combination therapy was highly selective for mammary carcinoma cells. Also, heat-induced gene expression could be an excellent tool for targeted cancer gene therapy (368).

The combination of hyperthermia with hormone therapies is also a striking method. When applied to the prostate (369) all eight participants responded locally, and in vitro, quercetin and tamoxifen sensitize human melanoma cells to hyperthermia (370). The combination of hyperthermia with enzyme-therapy (371), PDT (372), gene therapy (373), immune- (374) and other supportive therapies (375) is also being investigated.

DISCUSSION
The Challenges of Classical Hyperthermia
The history of success and the broad range of convincing results of oncological hyperthermia are not enough at the present moment to assure all medical experts of the feasibility of hyperthermia in oncology. Normally, a drug or method which has shown such clinical and research achievements and applicability would have been readily applied in therapeutic practice. Presently, less than 2% of cancer patients who would be indicated for hyperthermia, receive the therapy (376). Some health providers in clinical practices, decision makers, and professional insurers reject, or at least remain disinterested in considering hyperthermic therapy in oncology. Various factors contribute to the situation, including professional and emotional factors and a lack of knowledge of hyperthermia among doctors.

One of the most important factors contributing to the aversion of doctors to hyperthermia is the absence of an accepted definition of hyperthermia in oncology. Different websites, authors and industry leaders make use of different definitions and descriptions. Additionally, the technical challenges of heating up deep-seated tumors in a body create doubt. The number of devices available commercially is substantial, and in many instances manufacturers refer to the efficiency of their treatment based on phantom measurements, while relying on the clinical outcomes from other devices to prove efficacy. There is a concern that due to the variation in techniques and control mechanisms, not all of the techniques should be classified under one umbrella, and therefore the clinical data cannot be expected to be applicable to all of the techniques (377, 378). The broad assumption that all techniques have equal clinical outcomes is one consequence of the absence of a clear definition of oncological hyperthermia. This opens the door for techniques without sufficient clinical data to be marketed which, combined with a general inadequacy of knowledge about hyperthermia methods in oncology, supports the negative skepticism toward hyperthermia. The wide versatility of oncological hyperthermia applied to almost all types of tumors and at all stages of disease, with and without conventional therapies, fosters the “miracle universality” mind set of some clinicians which is naturally rejected by the professional community. The broad range of applications demands more and deeper research studies, and greater efforts to understand the impact of hyperthermia in malignant diseases. The responsibility for curing patients puts an enormous burden on the doctor, who will be hesitant to take responsibility for a therapy which is not completely understood or accepted. The relative simplicity and broad application of the heating techniques may cause uneasiness among professionals.
who expect the better defined protocols which they are familiar with for conventional therapies.

The difficulty determining the exact intratumoral temperature safely and accurately, along with the different effects observed at different temperatures, has resulted in significant debate amongst the hyperthermia community regarding the thermometry as a dosing and safety control parameter. Some techniques aim for temperatures in excess of 41°C, relying on the effects of higher temperatures on the DNA double strand break repair processes (379), while other techniques rely on moderate temperature increases of between 39 and 41°C (380), at which the improved perfusion enhances the effects of ionizing radiation on the tumor, or increases the drug delivery and reaction rate of chemotherapy in the tumor. Improved perfusion is seen in temperature increases as mild as 2°C (381) and at such mild temperatures, the immune modulating effects become more dominant (119).

While attempts to define hyperthermia based on the temperature alone have been made (141), the variation in effects at different temperatures leaves a sense of incompletion in the definition of hyperthermia. This has allowed researchers to attribute the lack of positive results in some studies to inadequate heating or incorrect technique. For example, one study using a capacitive heating technique failed to show a benefit with the addition of hyperthermia to chemoradiotherapy for cervical cancer in a phase three study, despite measuring intratumoral temperatures in excess of 41°C (382). While another phase three randomized controlled study has shown significant benefit to the addition of mEHT to chemoradiotherapy for cervical cancer, despite not applying thermometry and likely only reaching temperature increases of 2°C (199). Analyses by Koersen et al. (380) have shown an association between temperature and outcome in their sample of patients treated with a radiative form of hyperthermia. It is our view that the problem lies with the dosing control measures, in other words the thermometry, and that going forward a change in the dosing method is required.

A potentially more complete definition would refrain from citing temperatures and rather describe applied energy to induce the desired effects, as defined by Szasz et al. (383): “Oncological hyperthermia is a method for killing malignant cells by controlled thermal effects, and has the potential to sensitize complementary therapies while avoiding the destruction of healthy cells.” A shift in the definition away from the historically temperature dependent version, could provide a solution to the challenge of treating deep tumors. However not all techniques are able to accurately determine the energy absorption and a substantial reworking of some models would be required to align with this new proposed dosing concept. This would be a big ask to change the dosing concept for a field which is only now gaining momentum, and is likely to meet with resistance from users who are comfortable with temperature as the primary dosing and safety parameter. When looking at the new paradigm, the only technique which currently fits into the proposed model is mEHT and while there are many advantages, including safety and ease of use, this technique is also not perfect.

The basic principles of classical hyperthermia have also been questioned. The ancient notion that heating the tumor would, by the increased temperature, kill the malignant cells, is an oversimplified explanation because it fails to consider the complex interactions of the tumor environment and the reactions of the human body when exposed to heat, such as the potential acceleration of transport of metabolites to the tumor, which may provide the tumor with extra support.

The absence of a common dose-concept of oncological hyperthermia presents doctors with seemingly vague conditions, which is another driving factor in the low degree of acceptance of the method (384). The tumor is extremely non-homogeneous by its nature. The physiological, electromagnetic and thermal parameters change dynamically, varying the developed temperature in various parts of the target. The most effective challenger of homogeneous heating is again blood flow. In local treatments where the cooling blood flow creates a dynamic heating instability, the thermal non-equivalence of the various parts of the tumor, both in the macro and micro ranges, defines the thermal maps. The theoretically applied dose of hyperthermic action is the CEM. It refers, at 43°C, to “x” percent of homogeneity (noted as the CEM43°Cx) (385). The reference measurement of the dose is provided in in vitro experiments on the necrosis of a cell-line at 43°C. The temperature was arbitrarily chosen, and based on a literature review at the time, the theoretical model that for every 1 degree decrease in temperature, a twofold increase in exposure time was required to induce necrosis, was developed (386). The reference-point has none of the physiological parameters or molecular alterations which could be important for complex processes.

A further challenge is that the CEM43°Cx is too complicated and sometimes irrelevant (387): since it does not always correlate with clinical observations (348, 388). Its precise measurement is impossible in standard clinical conditions. The invasive temperature measurements are taken at discreet points, which is far too indefinite in such a non-homogeneous system, and the measurements cannot be taken as frequently as the treatment requires. In most publications, the medical staff measure the temperature intraluminally near the tumor. The lumen has much less of a “cooling” effect from blood flow than the tumor does, so the same energy absorption heats the intraluminal probe to a higher temperature, and there is no guarantee that the lumen is heated to the same energy flux or specific absorption rate (SAR) as the tumor. This is an indirect measurement of tumor-temperature and risks misleading the efficiency of the treatment.

Convincing experts in the clinical efficacy of the method is the next challenge. After a milestone publication by the Dutch Multi-Centre Alliance in The Lancet (185), expectations for hyperthermia were extremely high. The significant increase of the 4-year survival period for cervix carcinoma treated in combination with hyperthermia and radiotherapy, was a breakthrough. A repeated study however, did not show this difference (176), and the explanation (389) was the lack of a temperature reference point, a variation in methods, and thus a dose problem. A newer clinical study including a brachytherapy combination was also contraindicative (179). Importantly, the earlier clinical trials left unanswered questions. It was shown in 1996 (242) that radiotherapy with hyperthermia improved local control, compared to radiotherapy alone; however, the survival period was lower in the complete remission patients. This issue
with the contradiction between the local control and survival period was also measured on superficial tumors in a clinical study (334). The earlier observed (164) toxicity problems reappeared.

Statistical reproducibility is in any case challenging. The majority of hyperthermia treatments are provided for patients where conventional therapies alone offer no further outcome benefits. This condition selects the advanced patient population, whose care would be largely palliative without hyperthermia. It is a great challenge to collect the proper cohorts of patients for statistical evaluation, because the pre-treatments and the conditions of patients have huge variations. Researchers avoiding this contra-selected population usually treat locally advanced cases without detectable distant metastases. This, however, decreases the enthusiasm of clinicians who are expecting solutions for complicated cases when the conventional treatment arsenal fails.

Most preclinical research is in vitro cell-line or in vivo small animal models. A vast proportion of the experimental research uses hyperthermia alone, while in the clinical practice, it is primarily used as a complementary and synergistic addition to conventional therapies. The monotherapy application of hyperthermia measures the direct thermal cytotoxic effects, but in clinics the complementary application of hyperthermia sensitizes and improves the efficacy of the curative actions of conventional therapies. In many model experiments, hyperthermia was applied with a water-bath and a homogeneous water-temperature was used as the basis of CEM43°C Tx. Efforts are made rarely to conduct experiments similar to clinical applications, and which make use of various electromagnetic technical solutions. Another challenge related to the gap between research and clinical practice is the lack of human physiological effects included in the pre-clinical models. Furthermore, many animal experiments use artificially inoculated cancer cell-lines instead of naturally developed ones, which could differ from one another, especially when the tumor inoculation is not into the organ where the tumor would naturally grow. The systemic effects of local hyperthermia could face a challenge in small animal models, where the development of real metastases is relatively rare. Metastases are therefore modeled by injecting additional primary tumors into the animal.

The economic conditions are also not optimal for oncological hyperthermia. Most devices are expensive, have large installation and running costs, require costly labor and resources, and have much longer treatment times than do any other “gold standards of treatment.”

We have recognized the limitations and challenges of oncological hyperthermia. Recognizing the challenges is not enough to move forward, we need to formulate a method that can overcome the challenges and limitations. With this in mind, we propose a change in the paradigm of oncological hyperthermia.

Proposal for the Change of Paradigm

The proposed change moves away from the strict control of the temperature as an outcome and instead defines the treatment based on the selective action of the absorbed energy, which induces a temperature elevation. In this model, isothermal temperature is not a requirement. The raised temperature is a condition and a tool for work, but the goal is the selective elimination of malignant cells. When considering the temperature increase, the period of increased temperature is temporary as the body naturally tries to eliminate temperature differences which normalize after the completion of the treatment. The temperature characteristically seeks homogeneity, and the traditional dose refers to this homogeneous temperature in the targeted area. But the heat naturally spreads by conduction and convection processes. The heterogeneity of the target and the blood flow through the vascular network in the target limits the homogeneity of temperature. The blood flow transfers the heat from the target to the rest of the body, and this further complicates the thermometry.

Another confounding factor is the transition from vasodilation to vasoconstriction beyond a certain temperature $T_1$ in tumors. This is due to the growing intratumoral pressure and the walls of angiogenetic vessels, which lack the muscular structure to compensate for the increased pressure. Consequently, the value of $T_1$ depends on the kind of tumor, and its stage. In theory, if the $T_1$ is effectively achieved, then the vasocontracted tumor causes necrosis, which further blocks blood flow, reducing the cooling effects of the blood and makes it possible to achieve temperatures above the reference 43°C of CEM43°C Tx, dose counting, which results in necrosis. However achieving and maintaining these temperatures are problematic. Additionally, the high gradient of blood flow in the outer region of the tumor (where active proliferation occurs) caused by the temperature growing over $T_1$ increases the risk of dissemination and the advancement to distant the metastases.

Song observed the problem of $T_1$ and opened a pioneering discussion on the topic (390). His proposal focused on mild, fever range hyperthermia. Song argues that the fever range is hot enough to improve perfusion and support complementary therapies depending on blood-transport, but not hot enough to promote the invasion and dissemination of the malignant cells. This idea closely represents the fine line between toxicity and therapeutic gain seen in other modalities.

The mild heating, when the temperatures do not exceed $T_1$, stimulates general immune reactions. It was observed that the cytotoxicity of NK-cells sharply drops above 41°C (391, 392), and the activity of the immune-cells decreases. However, in the mild range an induced immune-effect is observed (393), even in the preoperative application (394). The suppression of the immune-activity by the high local tumor-temperature in LRHT is often neglected, with an assumption that new immune cells from the non-heated areas will be delivered.

The SAR characterizes the absorbed power in the target. The SAR and the temperature distribution do not correlate (395). The heating of unwanted materials in the target and the loss of energy due to the intensified blood flow and the massively forced surface cooling, modify the correlation between the SAR and temperature.

The new paradigm, described in detail in the following paragraphs, considers the regulation of blood flow, limiting it to avoid dissemination, but at the same time forming a synergy with complementary therapies, as well as inducing the appropriate distortion to the malignant cells. The goal is to ensure maximum
absorption of the thermal energy (heat), within the malignant cells, without considerable heating of their environment and without heating the healthy surroundings at the same time. Heterogenic (selective) heating could be achieved by considering certain biophysical and physiological differences between cancer cells and their microenvironment from the non-malignant tissues in their vicinity (28). The clinically measured situation shows that a mild temperature gain together with a sufficient increase of blood flow, supports complementary therapies (28).

In the selection process, mEHT utilizes the fact that the cancer cells have increased proliferation, requiring appropriate nutrients, mainly glucose. The nutrients in the aqueous solution, such as the tissue electrolytes, represent higher ionic concentrations, which presents less resistivity to the electric current which is pushed through the target by the device. The current density in the tumor is selectively increased due to its lower impedance (396), and thus the lesion is selected. The microenvironment of the autonomous cancer cells differs from that of the healthy network. Healthy cells are connected, and their network enables the coordination of the cellular activities and mechanisms. Adding to the effects of the increased extracellular ions on the conductivity and permittivity of malignant tissue are the necrotic regions and the increased water concentration (although this does not result in the dilution of the electrolytes, it is only a change in volume which further decreases the conductivity and increases permittivity). Malignant tissues will therefore absorb more energy than the healthy tissues.

After the selection of the malignant tissue over the healthy tissue by mEHT (397), the energy absorption is focused in the malignant tissue. In a simulation on the nanoscopic effects on the cell membranes, Papp et al. demonstrated regions of focused energy absorption (398) which are believed to be the clusters of transmembrane proteins (rafts) on the membranes of cancer cells (399, 400). The malignant cells have relatively high raft density compared to the non-malignant neighbors (401), which appears to aid the selection further. This means that the energy-absorption could heat the membrane to at least 3°C higher than its surrounding extracellular electrolyte (402, 403). The full process from the temperature point of view shows the rise in temperature of the raft, representing the gradient generated by the mEHT action. In principle, the rafts will heat up the malignant cell and that heats the entire tumor. In this method the tumor temperature remains mildly increased, while the rafts have high energy-absorption. The goal is not to seek necrotic cell's death, but to initiate an apoptotic signal transduction producing immunogenic cell's death by causing damage to the cell membrane.

In order to target certain molecules within the tissue, the dispersion type at which the targeted molecules are affected must be determined and the frequency that is within that dispersion range must then be applied. In the case of mEHT, the target is the cellular membrane and the lipids and transmembrane proteins embedded in the membrane, and this is achieved by applying a frequency in the range of beta/delta-dispersion which targets these transmembrane proteins and lipids. The high beta/delta-dispersion causes an increased energy-absorption at the cell membrane of malignant cells which, as described previously, is due to the dipolar relaxation of membrane-bound and protein-bound water, and the rotation and relaxation of the of proteins and polar-side chains.

After this selection, the final step is the excitation by energy-absorption. Due to various physiological effects – various transport processes involving large (blood, lymph, nerve), small (junction, cadherins) and intracellular (cytoskeletons) transport mechanisms – mEHT applies a pattern recognizing and harmonizing fractal amplitude modulation (404) to keep the natural homeostatic control as effective as possible. The radiofrequency waves undergo amplitude modulation, at a frequency of 1/f (fractal range) which is out of the range of the malignant tissues and therefore causes increased and selective agitation of the malignant cells (404) while maintaining the natural homeostatic control as effective as possible.

The mEHT process induces apoptosis by extrinsic excitation of several signal pathways (405–407). In vitro, the effects of mEHT as compared to conventional hyperthermia at the same temperature are significantly more profound (408). The strong synergy between the temperature and the field effects has been demonstrated (409). The electromagnetic excitation of the transmembrane proteins has an additional advantage: the promotion of apoptosis (410). The goal is the extrinsic excitation of the various apoptotic pathways (411), including the caspase dependent and independent processes (Figure 9). The extrinsic excitation targets the DR-5 death receptor in a complex with FADD and FAS molecules going through on both the path involving Caspase 8 and that involving Caspase 9 (Cas8 and Cas9) (408). It blocks the XIAP by Smac/Diabolo (412) and Septin4 (413), preventing its action against the signal transfer, and develops the apoptosis inducing factor (AIF) (408, 414) in a caspase-independent process.

The non-homogeneous induced heating in mEHT allows the application of a high precision hyperthermia (415), which is personalized (416). The well-focused energy absorption reduces the heating of non-malignant parts in the target, reducing the energy loss and increasing the efficacy of the treatment. The efficiency of the technique means that there is minimal loss of energy and most of the energy is deposited within the malignant tissue. This allows for the use of the forwarded, or incoming, energy as a measurement of the dose. The selected absorption of the power of the incident radiofrequency current allows us to introduce a simpler and biophysically accepted dose definition for the control of the medical process. This dose represents the same concept as is used in ionizing radiation, the Gray (Gy = J/kg). This dose is defined by absorbed energy, which is the product of the provided power with time. The absorbed power per unit mass is the SAR (W/kg). Connections between the SAR and the local temperature depend on physiological feedback mechanisms, a dependency which introduces a non-linearity to this relationship (417).

In mEHT, the selective heating allows for a good assumption of the amount of absorbed energy, and as a result the incident energy (J) can be used as the dose. An experiment in which artificial gold nanoparticles were added from suspension to the targeted volume and then heated with mEHT, demonstrates the selectivity of the technique (418). During the experiment, HepG2
FIGURE 9 | The five steps of the energy-selective mechanism causing apoptotic cell-destruction. The energy-absorption step (the 3rd one) is hyperthermic, proven by Arrhenius plot. The 4th step belongs to fractal-physiology. Extrinsic excitation and the apoptotic pathways to kill the cell with the mEHT method. Three variants of apoptotic signal pathway are used, and the blocker (XIAP) is blocked, preventing its action from limiting the signal transfer.

cells were suspended and incubated with gold nano-particles and exposed to mEHT or a hot water bath. Using mEHT, no increase in temperature was detected and cell death rates were not increased. The authors concluded that the cell-incorporated gold nanoparticles reduced the cell selectivity and had a protective action to mEHT. The additional artificial particles in the naturally selected membrane rafts produce a higher quantity of energy-absorbing material while the cell-killing effect decreases. This is explained by the competing energy absorption between the (useful) membrane rafts and the nanoparticles incorporated into the cell, demonstrating that without the effects on the membrane rafts, the treatment does not have the desired effects.

The extracellular electrolyte of the selected malignant cells is heated more than the membrane-isolated cytosol. This is a result of the insulating effect of the cell membrane on the intracellular environment, which is described mathematically in an article by Szasz et al. (122). In the article, the tumor cells are described as collections of various electrolytes encapsulated by highly polarized thin films (various membranes), and the cells are suspended in an electrolyte rich solution (extracellular matrix). The thickness of the cell membrane ranges between 4 and 10 nm with a potential of between 70 to 90 mV and a capacity of 106F/m2. Additionally, the absorbed energy is at least two orders of magnitudes higher in the extracellular than in the cytosol (419, 420). The membrane acts as a barrier for electric field penetration into the cell, provided the applied frequency is not too high. The actions (excitation) are therefore primarily on the extracellular electrolytes and not on the intracellular electrolytes. These characteristics cause the membrane to act as a barrier for electric field penetration into the cell, provided the applied frequency is not too high. The actions (excitation) are

FIGURE 10 | Immunogenic treatment with mEHT. The induced immunogenic cell-death presents the genetic information to DCs forming antigen presenting cells (APCs) and tumor-specific killer cells which are active all over the system. It is an in situ, real-time process.
therefore primarily on the extracellular electrolytes and not on the intracellular electrolytes.

FUTURE PROSPECTS

The malignancy is a systemic disease. The goal of conventional LRHT is to eliminate the tumor, both with the highest achievement being declared as the reaching of complete remission. However, the appearance of metastases or relapses drastically limit the overall survival period of the patient. Chemotherapy or other systematically administered compounds (like check-point inhibitors, enzymes etc.) act systemically, with many variants in methods to activate personal immune actions against cancer. The challenge, however, is the highly adaptive hiding strategy of malignant cells, which protects them from the natural attacks of immune cells. An appropriate approach would therefore be to free the hidden genetic information of tumor cells and help the body to recognize and naturally kill the malignant cells. This could be achieved by stimulating immunogenic cell's death, which results in the freeing of the genetic information from the tumor. This information may mature the dendritic cells (DCs). The matured DCs form CD4+ and CD8+ (helper and killer) T-cells with appropriate tumor-specific information, preparing them for tumor-specific immune attack (54). Immune preparation through antigen presentation could be achieved using an off-situ, extracorporeal, laboratory process as well.

There is also potential to include the mEHT treatments as a method of immune-modulation (421) to non-invasively stimulate the maturation of DCs. The stimulation of apoptosis during mEHT treatments could result in antigen presentation promoting the generation of CD4+ and CD8+ T-cells in situ inside the tumor (Figure 10).

A complication of mEHT immune treatment, however, occurs when the immune-status of the patient is weak. In this case, independent immune support is necessary through the offering of active DCs and macrophages. Antigen presenting cell (APC) production could occur when the immature immune-cells are available, but the high local temperature blocks their activity.

There is potential that the required cells are available outside of the treatment field (in the non-heated regions) and that these could be delivered to the tumor location after the heating is finished. Unfortunately, however this is not sufficient for in situ APC production. The immunogenic cell-death and subsequent APC formation is a complex process, requiring the production of a set of damage associated molecules (DAMPs) (422) which have to be available in a specific time sequence at the place of the formation of the APCs (Figure 11). The tumor-specific immune action could subsequently attack the malignant cells all over the body, irrespective of their distance from the treated primary lesion. The systemic abscopal effect could be enhanced by an immune-stimulating process (423), or by injected immature DCs (424), to improve APC formation. This immune action would work like a vaccination, with subsequent attacks by the same tumor being ineffective (425).

CONCLUSION

Hyperthermia is a complex field, and it is further complicated by the variation in available techniques and the effects noted at different temperatures using the various techniques. The exact mechanisms of hyperthermia as a sensitizer are still not fully understood with debates on topics such as whether the inhibition of DNA repair is achieved at temperatures below

![FIGURE 11](image-url) The molecular details of the immunogenic action of mEHT. The set of damage associated molecules (DAMP) has an important messenger role. The HSP is liberated from the cytosol, and becomes a game-changer: instead of protecting the tumor-cell, it helps to destroy it.

![FIGURE 12](image-url) Development of the locoregional hyperthermia methods in oncology. The trend is in the direction of immune effects, demanding a new paradigm in hyperthermia.
41°C, the impact of improved perfusion, and the timing of hyperthermia treatments, still underway (141, 380, 381). Many of the mechanisms of hyperthermia are still theoretical. For example, the inhibition of DNA repair at temperatures in excess of 41°C has been demonstrated in vitro, but the required temperature in vivo cannot yet be proven due to thermometry challenges and difficulty obtaining tumors samples immediately before and after treatment in patients. The existence of membrane rafts is also not yet a widely accepted concept, although the membrane rafts fit with the model explaining the mechanisms behind mEHT. The effects of fractal range of modulation on the RF-waves in mEHT are not yet widely understood, however the hyperthermia community is recognizing the effects of the modulation and separate to the effects of heating (426). Pre-clinical and clinical studies demonstrated similar outcomes using lower temperatures with the addition of the amplitude modulation as compared to the same temperature with other heating techniques (199, 384, 412).

The immune effects at milder temperatures are intriguing, especially when considered parallel to the evolution of immunotherapies in oncology. The immunomodulating effects of hyperthermia are driving the research in hyperthermia in the direction of a more systemic and integrated modality in field of immuno-oncology. Immuno-oncology is an evolving field and the next few years are likely to shed more light on the interaction between the immune system and malignancies, and subsequently on drugs, ionizing radiation, and hyperthermia and the immune system. It is our view that this is the direction we can expect hyperthermia to move toward and we expect more research available on the immuno-modulating effects of hyperthermia, and the synergy between these effects and immunotherapies and radiotherapy.

The challenges with thermometry continue to plague the field with uncertainty, and the lack of thermometry in mEHT treatments causes a level of discomfort amongst clinicians who are still of the opinion that temperature is needed as a measure of treatment efficiency. Changing the dosing concept is an uncomfortable task for some clinicians and the discussions around the topic are continuing. When considering hyperthermia as a field, there is sufficient evidence from phase III randomized controlled trials to motivate the inclusion of hyperthermia in clinical protocols. However when considering each device and technique alone, the number of studies is limited. This leaves the clinician in a position where professional judgment and a good understanding of the field must guide the choice of technique, based on desired outcomes, resources, and feasibility. In the coming years we expect, as interest in the field grows, more studies on different technologies allowing for a comparison between effects and the development of protocols focusing on the techniques which have demonstrated improved outcomes.

The global market and healthcare is under pressure and technologies which are affordable and simple to use will become more important as healthcare systems around the world struggle under COVID-19 pandemic. The pandemic is likely to leave scars which could take years to overcome in some countries. We predict that there will be a shift toward the more simple and affordable heating techniques that can be easily taken up and integrated into the workflows at clinics. The COVID-19 pandemic has forced clinicians to think out of the box and to plan patient care to be as streamlined and effective as possible. Networking and the formation of multidisciplinary teams and improved collaboration between various medical fields and professionals has become more important. With this in mind, the need to apply a synergistic and multi-faceted approach to oncology protocols has been highlighted, and the uptake will likely be greater for technologies that can trigger systemic responses, as well as local responses.

It is our view that non-isothermal heating using mEHT has the potential to solve the old challenges and to usher in a new era of hyperthermia in oncology. The heterogenic molecular excitation demonstrated in preclinical studies on mEHT promotes tumor-specific immune-reactions which aligns with the shift toward immuno-oncology (Figure 12). Further understanding of the mechanisms involved in immuno-oncology will support the advancement of the field toward the direction of treating the patient as a whole system.

**AUTHOR CONTRIBUTIONS**

S-YL made broad literature research, categorized, and summarized it. GF helped the literature research in chemotherapy aspects. AMS evaluated the pathology aspects of the manuscript. GF and AMS wrote the manuscript. GS helped in search of the literature and its ordering as well as evaluation. AS investigated specific biophysical elements of the document and supervised the findings of the manuscript preparation project. CM added her wide practical expertise in thermo-radi chemotherapy, evaluated the clinical aspects of the manuscript, and verified the whole manuscript and finalized it. All authors discussed the results and contributed to the final manuscript.

**REFERENCES**

1. Lurito PW. The message was electric. *IEEE Spectrum*. (1984) 21:84–96. doi: 10.1109/MSPEC.1984.6370468
2. Weiss TF. *Cellular Biophysics. Transport*. (Vol. 1). Cambridge, MA: MIT Press (1996).
3. Head JF, Wang F, Lipari CA, Elliot RL. The important role of infrared imaging in breast cancer. *IEEE Eng Med Biol Mag*. (2000) 19:52–7. doi: 10.1109/51.844380
4. Gautherie M. *Temperature and Blood Flow Patterns in Breast Cancer During Natural Evolution and Following Radiotherapy. Biomedical Thermology*. New York, NY: Alan R. Liss (1982). p. 21–4.
5. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. *Int J Hyperthermia*. (1999) 15:79–107. doi: 10.1080/0265673992857656
6. Busch W. Uber den einfluss welche heftigere erysipeln zuweilig auf organisierte neubildungenausuben. *Vhr Naturhist Preuss Rhein Westphal.* (1866) 23:28–30.
7. Seegenschmiedt MH, Vernon CCA. Historical perspective on hyperthermia in oncology. In: Seegenschmiedt MH, Fessenden P, Vernon CC editors. *Thermoradiotherapy and Thermochemo therapy, Biology, Physiology and Physics*. (Vol. 1), Berlin: Springer Verlag (1995). p. 3–46. doi: 10.1007/978-3-642-57858-8_1
33. Datta NR, Ordonez SG, Gaipl US, Paulides MM, Crezee H, Gellermann J, et al. Quality assurance protocol for superficial and deep hyperthermia systems established by the Hellenic Association of Medical Physicists (HAMP) in cooperation with the Hellenic Society of Oncologic Hyperthermia (HSOH): A study based on European Society for H. J. BÜON. (2018) 23:491–9.
34. Triantopoulou S, Platoni K, Antypas CE, Karaiskos P, Armpilis C, Uzunoglu N, et al. Quality assurance protocol for superficial and deep hyperthermia systems established by the Hellenic Association of Medical Physicists (HAMP) in cooperation with the Hellenic Society of Oncologic Hyperthermia (HSOH): A study based on European Society for H. J. BÜON. (2018) 23:491–9.
35. Lagendijk JJ, Van Rhoon GC, Hornsleth SN, Wust P, De Leeuw AC, Schneider CJ, et al. ESHQ quality assurance guidelines for regional hyperthermia. Int J Hyperth. (1998) 14:125–33. doi: 10.1080/0266739980190212-M
36. Doblícek Třfná H, Schmidt M, van Rhoon GC, Kok HP, Gordeyev SS, Lamprecht U, et al. Quality assurance guidelines for interstitial hyperthermia. Int J Hyperth. (2019) 36:277–94. doi: 10.1080/02656736.2018.1564155
37. Bruggmoser G, Bauchowitz S, Canters R, Crezee H, Ehmann M, Gellermann J, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlentherapie und Onkol. (2011) 187:605–10. doi: 10.1002/sot.20611-1145-x
38. Kufe D, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, et al. Cancer Medicine. Hamilton: BC Decker Inc (2003).
39. Halperin EC, Wazer DE, Perez CA, Brady LW. Principles and Practice of Radiation Oncology. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins (2004).
40. DeVita VT, Hellman S Jr., Rosenberg SA. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins (2004).
41. van der Zee J. Heating the patient: a promising approach? Ann Oncol. (2002) 13:1173–84. doi: 10.1093/annonc/md280
42. Wust P, Felix R, Deulfhard P. Kunstliches feber gegen krebs. Spektr Wissensc. (1999) 79:76–84.
43. Datta NR, Puric E, Klinbiel D, Gomez S, Bodis S. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiation Oncol Biol Phys. (2015) 94:1073–87. doi: 10.1016/j.ijrobp.2015.12.361
44. Datta NR, Stutz E, Gomez S, Bodis S. Efficacy and safety evaluation of the various therapeutic options in locally advanced cervix cancer: a systematic review and network meta-analysis of randomized clinical trials. Int J Radiation Oncol Biol Phys. (2018) 103:411–37. doi: 10.1016/j.ijrobp.2018.09.037
45. Helm JH, Miura JT, Glenn JA, Marcus RD, Larriegue G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesotheloma: a systematic review and meta-analysis. Ann Surg Oncol. (2015) 22:1686–93. doi: 10.1245/s10434-014-4978-4
46. Datta NR, Rogers S, Klingerbiel D, Gómez S, Puric E, Bodis S. Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses. Int J Hyp. (2016) 37:809–21. doi: 10.1016/j.ijhpy.2016.1195924
47. Roussakov S. Regional hyperthermia with neoadjuvant chemotherapy for treatment of soft tissue sarcoma. JAMA Oncol. (2018) 4:483492. doi: 10.1001/jamaoncol.2018.5296
48. Roussakov S. Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma. Lancet Oncol. (2017) 18:e629. doi: 10.1016/S1470-2045(17)30643-5
49. Roussakov S. Critical analysis of electromagnetic hyperthermia randomized trials: dubious effect and multiple biases. Conf Pop Med. (2013) 2013:412186. doi: 10.1155/2013/412186
50. Hornbach NB. Is the community radiation oncologist ready for clinical hyperthermia? RadioGraphics. (1987) 7:139–41. doi: 10.1148/radiographics.7.1.3329357
51. Schirrmacher V. Quo vadis Cancer Therapy?: Fascinating Discoveries of the Last 60 Years. Beau Basin: Lambert Academic Publishing, Omniscriptum Publishing Group (2017).
52. West BJ. Where Medicine Went Wrong: Rediscovering the Path to Complexity. London: World Scientific Publication (2006). doi: 10.1142/6175
54. Szaa S, Szaa O, Szaa N. Physical background and technical realization of hyperthermia. In: Barzonio GF; Hager ED editors. Hyperthermia in Cancer Treatment: A Primer. Berlin: Springer Verlag (2006).

55. Milligan AJ. Whole-body hyperthermia induction techniques. Cancer Res. (1964) 24:8689–72a.

56. Suáñez AV, Ivanov GV, Efremov AV, Tchervov R. Whole body hyperthermia at 43.5–44°C: dream or reality? In: Barzonio GF; Hager ED editors. Hyperthermia in Cancer Treatment: A Primer. New York, NY: Springer Science (2006). p. 228–32.

57. Heckel M. Ganzkörperthermodynamik und Fiebertherapie – Grundlagen und Praxis. Stuttgart: Hippokrates (1990).

58. Ardenne Von A, Wehner H. Extreme Whole-Body Hyperthermia with Water-Filtered Infrared-A Radiation, NCB! Bookshelf, Landes Bioscience, Madame Carie Bioscience Database (2005). Available online at: http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=eurekah&part=A46701 (accessed November 24, 2009).

59. Srobl B. 6 Jahre ganzkörperthermodynamik kombiniert mit chemotherapie beim ovarialkarzinism, Dolphin-0- und -1-Studie. Hyperther Sympose. (2006) 6:22–3.

60. Ash SR, Steinhart CR, Curfman MF, Gingerich CH, Sapir DA, Ash EL, et al. Extracorporeal whole body hyperthermia treatments for HIV infection and AIDS. ASAIO J. (1997) 43:M830–8. doi: 10.1097/00002480-199709000-00101

61. Vaupel P, Piazza H, Müller W, Nötter M. Biophysical and photobiological basics of water-filtered infrared A hyperthermia of superficial tumors. Int J Hys. (2015) 35:26–36. doi: 10.1002/mib.1449169

62. Kelleher DK, Thews O, Rzeznik J, Scherz A, Salomon Y, Vaupel P. Water-filtered infrared A-radiation: a novel technique for localized hyperthermia in combination with bacterioclorthophyll-based photodynamic therapy. J Hyperthermia. (1999) 15:467–74. doi: 10.1002/0265739928546

63. Follette C, Liebscher S, Mouw T, Al-Kasspooles M. Levendag PC, Marijnissen HPA, de Ru VJ, Versteeg JA, van Rhoon GC, Suriyanto Ng, Ng EYK, Kumar SD. Physical mechanism and modeling of heat generation and transfer in magnetic fluid hyperthermia through Néelian heat generation and transfer in magnetic fluid hyperthermia through Néelian hyperthermia at 43.5-44.(1984) 44:4869s–72s.

64. Zhang G, Zhu Y, Liu C, Chai G, Czi R, Zhang Z. The prognosis impacto of hyperthermia in the multidisciplinary treatment of malignant tumors. Integrative Cancer Therapies. (2019) 18:1–11. doi: 10.1177/1537474719876345

65. Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic intraoperative chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) in advanced ovarian cancer: the meta-analysis. Gastrointest Oncol. (2019) 24:2009).

66. Lotti M, Capponi MG, Piazzalunga D, Poiasina E, Pisano M, Manfredi R. Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic intraoperative chemotherapy (HIPEC) and Cytoreductive Surgery (CRS) in advanced ovarian cancer: the meta-analysis. Gastrointest Oncol. (2019) 24:2009).

67. Magin RL, Peterson AF. Noninvasive microwave phased arrays for local hyperthermia with an annular phase array. IEEE Trans Biomed Eng. (1984) 31:106–11. doi: 10.1109/TBME.1984.325376

68. Felix R, Deuflhard P, Wust P. Kunstliches Fieber Gegen Krebs beim ovarialkarzinom, Dolphin-0- und -1-Studie. Spektrum der Wissenschaft (1999). p. 78–84.

69. Issels RD, Adbel-Rahman S, Wendtner C, Falk MH, Kurze V, Sauer H, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for colorectal cancer: an update review. Int J Hyperthermia. (1998) 14:1–8. doi: 10.1080/15368370600719042

70. Issels R. Hyperthermia combined with chemotherapy – biological rationale, clinical application, and treatment results. Onkologie. (1999) 22:374–81. doi: 10.1159/000026986

71. Wust P, Fahling H, Wlodarczyk W, Sadeghirad B, et al. Antenna arrays in the sigma-eye applicator: interactions and transforming networks. Med Phys. (2001) 28:1793–805. doi: 10.1118/1.1388220

72. Felix R, Deuflhard P, Wust P. Kunstliches Fieber Gegen Krebs. Berlin: Spektrum der Wissenschaft (1999). p. 78–84.

73. Hoshino T, Sato T, Masai A, Sato K, Matsuki H, Seki K, et al. Conduction Star WM. Interaction of interstitial photodynamic therapy and interstitial heating in a rat rhabdomyosarcoma – A pilot study. Int J Radiation Oncol Biol Phys. (1989) 14:4689–91. doi: 10.1016/0360-3016(89)90906-2

74. Pearson AS, Izzo F, Fleming RYD, Ellis LM, Delrio P, Roh MS, et al. Intraperitoneal radiofrequency ablation of cryoablation for hepatic malignancies. Amer J Surg. (1999) 178:592–8. doi: 10.1016/S0002-9610(99)00234-2

75. Ellis LM, Curley SA, Tanabe KK. Radiofrequency Ablation of Cancer. New York, NY: Springer Verlag (2004).

76. Hoshino T, Sato T, Masai A, Katsuji S, Seki K, et al. Conduction Hyperthermia in Cancer Treatment: A Primer. Berlin: Springer Science (2006). p. 228–32.
and Brownian relaxation: a review. BioMed Eng OnLine. (2017) 16:36. doi: 10.1186/s12938-017-0327-x
96. Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia: a biophysical approach to cancer treatment via intracellular temperature and biophysical alteration. Med Hypotheses. (1979) 5:83–102. doi: 10.1016/0306-9877(79)90636-X
97. Rabin Y. Is intracellular hyperthermia superior to extracellular in the thermal sense? Int J Hyperthermia. (2002) 18:194–202. doi: 10.1080/026567301161713
98. Jordan A, Scholtz R, Wust P, Faehling H, Felix R. Magnetic fluid hyperthermia (MFH): Caner treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magnetic Mater. (1999) 201:413–9. doi: 10.1016/S0304-8853(99)00088-8
99. Nishide OJ. The role of magnetic induction techniques for producing hyperthermia. In: Anghileri JJ, Robert J editors. Hyperthermia in Cancer Treatment. (Vol. II), Boca Rotan, FL: CRC Press (1985), p. 141–54.
100. Nishide SM, Ueno S. A method of localized hyperthermia by using a figure-of-eight coil and short-circuit rings. International Conference of the IEEE Engineering in Medicine and Biology Society. San Diego, CA: (1993). p. 1447–8.
101. Jojo M, Murakami A, Sato F, Matsuki H, Sato T. Consideration of handy approach to cancer treatment via intracellular temperature and biophysical approach. J Magn Magnetic Mater. (2001) 27:2944–6. doi: 10.1109/29515355
102. Hiraki Y, Nakajo M, Miyaji N, Takeshita T, Churei H, Ogita M. Effectiveness of RF capacitive hyperthermia combined with radiotherapy for stages III and IV pro-hypopharyngeal cancers: a non-randomized comparison between thermoradiotherapy and radiotherapy. Int J Hyperthermia. (1998) 14:593–4. doi: 10.3109/02656739809018247
103. Harima Y, Nagata K, Harima K, Oka A, Ostapenko VV, Shikata N, et al. Phase III trial of preoperative thermoradiotherapy in the treatment of urinary bladder cancer. Int J Hyperthermia. (1994) 10:31–40. doi: 10.3109/02656739400909329
104. Masunaga SI, Hiraoko M, Akuta K, Nishimura Y, Nagata Y, Jo S, et al. Abscopal killing by hyperthermia, procaine and radiation. In: Streffer C, van Beuningen D, Dietzel F editors. Cancer Therapy by Hyperthermia and Radiation Oncology: what evidence is necessary? Munich: Urban & Schwarzenberg (1978), p. 19–28.
105. Lee S-Y, Szigeti GP, Szasz AM. Oncological hyperthermia: the correct dosing of effect. Open J Biophys. (2018) 9:31–48. doi: 10.4236/ojbiphy.2018.81004
106. Higuchi H, Szigeti GP, Szasz A. Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med. (2013) 2013:672873. doi: 10.1155/2013/672873
107. Lee S-Y, Szigeti GP, Szasz AM. Oncological hyperthermia: the correct dosing in clinical applications. Int J Oncol. (2019) 54:427–43. doi: 10.3892/ijo.2018.4645
108. Nishida T, Akagi K, Tanaka Y. Correlation between cell killing effect and cell-membrane potential after heat treatment: analysis using fluorescent dye and flow cytometry. Int J Hyperthermia. (1997) 13:227–34. doi: 10.3109/026567397012385
109. Weiss TF. Cellular Biophysics. Electrical Properties. (Vol. 2). Cambridge, MA: MIT Press (1996).
110. Wiedermann GJ, Feyerabend T, Mentzel M. Thermochrometherapy: grund der die kombinationsbehandlung mit hyperthermie und chemotherapie. Focus Med. (1994) 11:44–50.
111. Frey B, Rubner Y, Wunderlich R, Weiss EM, Pockley AG, Fietkau R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation – implications for cancer therapies. Curr Med Chem. (2012) 19:1751–64. doi: 10.2174/092967612800099911
112. Houghton PJ, Barbone F, Nakanishi K, Bodey GP, Bodey GP, et al. Induction of abscopal immunity by hyperthermia. Cancer Res. (1989) 49:4708–13. doi: 10.1158/0008-5472.CAN-89-0943
113. Lee et al. What is the Horizon for 2020?
Hyperthermia and Radiation. Munich: Urban & Schwarzenberg (1978). p. 160–2.

136. Hahn GM. The heat-shock response: effects before, during and after gene activation. In: Gautherie M editor. Biological Basis of Oncologic Thermotherapy. Berlin: Springer Verlag (1990). p. 135–59. doi: 10.1007/978-3-642-74939-1_3

137. Vapoul PW, Kelleher DK. Metabolic status and reaction to heat of normal and tumor tissue. In: Seegenschmiedt MH, Fessenden P, Vernon CC editors. Thermo-Radiotherapy and Thermo-Chemotherapy. Biology, Physiology and Physics. (Vol. I), Berlin: Springer Verlag (1996). p. 157–76. doi: 10.1007/978-3-642-57858-8_8

138. Kabakov AE, Gabai VL. Hyperthermic Oncology from Bench to Bedside. Singapore: Springer (2016). doi: 10.1007/978-981-10-0719-4

139. González-González D. Thermo-radiotherapy for tumors of the lower gastrointestinal tract. In: Seegenschmiedt MH, Fessenden P, Vernon CC editors. Thermo-Radiotherapy and Thermo-Chemotherapy. Biology, Physiology and Physics. (Vol. I), Berlin: Springer Verlag (1996). p. 105–19. doi: 10.1007/978-3-642-57858-8_7

140. Pence DM, Song CW. Effect of heat on blood flow. In: Anghireli LJ, Robert J editors. Hyperthermia in Cancer Treatment. (Vol. II), Boca Raton FL: CRC Press Inc (1986). p. 1–17. doi: 10.1201/9780429266546-1

141. van der Zee J, Vujaskovic Z, Kondo M, Sugahara T. The kadota fund. Int J Rad Oncol Biol Phys. (1989) 15:1407–13. doi: 10.1016/0360-3016(89)90237-4

142. Horsman MR, Overgaard J. Hyperthermia: a Potent Enhancer of Radiotherapy. Clinic Oncol. (2007) 19:418–26. doi: 10.1016/j.clon.2007.03.015

143. Oleson JR. Review eugene robertson special lecture, hyperthermia from the clinic to the laboratory: a hypothesis. Int J Hyperthermia.(1995) 11:315–22. doi: 10.3109/02656739509022467

144. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys. (1989) 16:335–49. doi: 10.1016/0360-3016(89)90470-7

145. van der Zee J, Truemiet-Donker AD, The SK, van Rhoon GC, Broekmeyer- Reurink MP, Reinhold HS. Low dose reirradiation in combination with hyperthermia: a palliative treatment for patients with breast cancer recurring in previously irradiated areas. Int J Radiat Oncol Biol Phys. (1988) 15:1407–13. doi: 10.1016/0360-3016(88)90237-4

146. Bicher JI, Al-Bussam N, Wolfstein LS. Thermotherapy with curative intent – breast, head, and neck, and prostate tumors. Deuts Zeitschrift Oncol. (2006) 38:116–22. doi: 10.1055/s-2006-952049

147. Molls M. Hyperthermia – the actual role in radiation oncology and future prospects. Strahlenther Oncol. (1992) 168:183–90.

148. Seegenschmiedt MH, Feldmann HJ, Weiss P. Hyperthermia – its actual role is radiation oncology. Strahlenther Oncol. (1995) 171:560–72.

149. Emami B, Scott C, Perez CA, Asbell S, Swift P, Montgomery KL, Simon E editors. Thermotherapy. In: Gautherie M editor. Radiotherapy for solid tumors. (Vol. 1), Berlin: Springer Verlag (2001). p. 105–19. doi: 10.1007/978-4-431-67035-3_45

150. Lepock JR. Celluar effects of hyperthermia: relevance to the minimum dose for thermal damage. Int J Hyperther. (2003) 23:252–66. doi: 10.1080/026567303100065042

151. Dewey WC. Arhenius relationships from the molecule and cell to the clinic. Int J Hyperther. (2009) 1:3–20. doi: 10.1080/02656730902747919

152. Datta NR, Rogers S, Ordonez SG, Puric E, Bodis S. Hyperthermia and Thermotherapy in the treatment of malignant brain tumors: preliminary results of clinical trials. Neurosurgery. (1990) 21:478–83. doi: 10.1093/jnci/80.5.607

153. Lee et al. What Is on the Horizon for 2020? A review and meta analysis. Int J Hyperthermia. (2016) 32:31–40. doi: 10.3109/02656736.2015.1099746

154. Tanaka Y. Thermal responses of microcirculation and modification of tumor blood flow in treating the tumors. In: Kosaka M, Sugahara T, Schmidt KL, Simon E editors. Theoretical and Experimental Basis of Hyperthermia. Thermotherapy for Neoplasia, Inflammation, and Pain. Tokyo: Springer Verlag (2001). p. 408–19. doi: 10.1007/978-4-311-67035-3_45

155. Van der Zee J, Vujaskovic Z, Kondo M, Sugahara T. The kadota fund. Int J Radiat Oncol Biol Phys. (1989) 171:560–72. doi: 10.1016/0360-3016(89)90237-4

156. Song CW, Choi IB, Nah BS, Sahu SK, Osborn JL. Microvasculature and perfusion in normal tissues and tumors. In: Seegenschmiedt MH, Fessenden P, Vernon CC editors. Thermoradiotherapy and Thermochemoerapy. (Vol. 1), (1993). p. 139–56. doi: 10.1007/978-3-642-57858-8_7

157. Song CW, Park H, Griffin RJ. Theoretical and experimental basis of hyperthermia. In: Kosaka M, Sugahara T, Schmidt KL editors. Thermoradiotherapy for Neoplasia, Inflammation, and Pain. Tokyo: Springer Verlag (2001). p. 394–407. doi: 10.1007/978-4-311-67035-3_44

158. Shinn KS, Choi IB, Kim IA, Kay CS. Thermoradiotherapy in the treatment of localized advanced nonsmall cell lung cancer. J Korean Soc Ther Radiol Oncol. (1996) 14:115–22. doi: 10.1016/0016-3002(95)85955-1

159. Kakora S, Yoshikawa T, Ohnishi T. Hyperthermic Oncology from Bench to Bedside. Singapore: Springer (2016). doi: 10.1007/978-981-10-0719-4

160. Stasz O, Stasz A. Considering skin physiology in capacitive-coupled hyperthermia. J Adv Phys. (1996) 11:3966–72. doi: 10.24297/jap.v11i18.206

161. Emami B, Scott C, Perez CA, Asbell S, Swift P, Grigsby P, et al. Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: a prospectively controlled randomized study by radiation therapy oncology group. Int J Radiat Oncol Biol Phys. (1996) 34:1097–104. doi: 10.1016/0360-3016(95)02137-X

162. Urano M, Dupe E. Hyperthermia and Oncology: Volume .2. Biology of thermal potentiation of radiotherapy. Utrecht: VSP BV Utrecht (1992).

163. Lee CK, Song CW, Rhee JG, Foy JA, Levitt SH. Clinical experience using 8 MHz radiofrequency capacitive hyperthermia in combination with radiotherapy: results of a phase II/I study. Int J Radiat Oncol Biol Phys. (1995) 32:373–45. doi: 10.1016/0360-3016(94)00608-N

164. Myerson RJ, Scott CB, Emami B, Sapoznik MD, Samulski TV. Phase I/I study to evaluate radiation therapy and hyperthermia for deep-seated tumors: a report of RTOG 89-08. Int J Hyperthermia. (1996) 4:449–59. doi: 10.3109/206567360902332532

165. Vernon CC, Harrison M. Hyperthermia with low-dose radiotherapy for recurrent breast carcinoma. Lancet. (1990) 336:1383.

166. Tanaka R, Kim CH, Yamada N, Saito Y. Radiofrequency hyperthermia for malignant brain tumors: preliminary results of clinical trials. Neurosurgery. (1998) 21:478–83. doi: 10.1093/jnci/80.5.607

167. Vasanthan A, Mitsumori M, Part JH, Zhi-Fan Z, Yu-Bin Z, Oliynychenko P, et al. Regional hyperthermia combined with radiotherapy for uterine cervical
cancers: a mutsititutional prospective randomized trial of the international atomic energy agency. Int J Rad Oncol Biol Phys. (2005) 61:145–53. doi: 10.1016/j.ijrobp.2004.04.057

177. Sahinbas H, Groenemeyer DHW, Boecher E, Szasz A. Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas. Deuts Zeitschr Onkol. (2007) 39:154–60. doi: 10.1055/s-2007-966020

178. Chi M-S, Yang K-L, Chang Y-C, Ko H-L, Lin Y-H, Huang S-C, et al. Comparing the effectiveness of combined external beam radiation and hyperthermia versus external beam radiation alone in treating patients with painful bone metastases: phase iii prospective randomized control trial. Int J Rad Oncol Biol Phys. (2017) 17:30. doi: 10.1016/j.ijrobp.2017.09.030

179. Zolciak-Siwinska A, Piotrkowicz N, Jonska-Gmyrek J, Nicke-Psikuta M, Michalski W, Kawczynska M, et al. HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy - a phase iii study. Radiother Oncol. (2013) 109:194–9. doi: 10.1016/j.radonc.2013.04.011

180. Imada H, Nomoto S, Tomimatsu A, Kosaka K, Kusano S, Ostapenko VV, et al. Local control of nonsmall cell lung cancer by radiotherapy combined with high power hyperthermia using an 8 MHz RF capacitive heating device. Int J Hyperthermia Oncol. (1999) 15:19–24. doi: 10.3191/thermalmedicine.15.15

181. Chihajd PN, Tamm M. Radiofrequency heat ablation for lung tumors: potential applications. Med Sci. Montit. (2003) 9:ED5–7.

182. Rietbroek RC, Schlithuis HS, Bakker PJM, van Dijk JD, Postma AJ, Gonzalez Gonzalez D, et al. Phase ii trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer. (1997) 79:935–43. doi: 10.1002/(SICI)1097-0424(19970301)79:5<935::AID-CNCR10>3.0.CO;2-3

183. Lee S-Y, Lee N-R, Cho D-H, Kim JS. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation. Oncol Lett. (2017) 14:6117. doi: 10.3892/ol.2017.6117

184. van Der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumors: a prospective, randomised, multicentre. Lancet. (2000) 355:1119–25. doi: 10.1016/S0140-6736(00)02059-6

185. Harima Y, Nagata K, Harima K, Ostapenko VV, Tanaka Y, Sawada SA. Randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia. (2001) 17:97–105. doi: 10.1080/02656730100001333

186. van der Zee J, Gonzalez DG. The dutch deep hyperthermia trial: results from a phase iii randomized controlled trial. Radiother Oncol. (2018) 105:13–8. doi: 10.1016/j.radonc.2016.02.010

187. Lutgens LC, Koper PC, Jobsen JJ, van der Steen-Banasik E, Creutzberg CL, van den Berg HA, et al. Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: results of the randomized RADHOC trial. Radiother Oncol. (2016) 120:378–82. doi: 10.1016/j.radonc.2016.02.010

188. Minnaar CA, Kotzen IA, Ayeni OA, Naidoo T, Tunner M, Sharma V, et al. The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase iii randomized controlled trial. PLoS One. (2019) 14:e0217894. doi: 10.1371/journal.pone.0217894

189. Matsumi N, Matsumoto K, Mishima N, Moriyama E, Turuta T, Nishimoto A, et al. Thermal damage threshold of brain tissue: Histological study of heated normal monkey brains. Neurol Med Chir (Tokyo). (1994) 34:209–15. doi: 10.2176/nmc.34.209

190. Haveman J, Siminia P, Wondergem J, van der Zee J, Hulshof MCCM. Effects of hyperthermia on the central nervous system: what was learnt from animal studies? Int J Hyperthermia. (2005) 21:473–87. doi: 10.1080/0265673050159079

191. Seed PK, Stea B. Thermoradiotherapy for brain tumors. In: Seegenschmidt MH, Fessenden P, Vernon CC editors. Thermoradiotherapy and Thermochemotherapy, Vol 2. Clinical Applications. Telos: Springer Verlag (1996).

192. Selker RG, Eddy MS, Deutsch M, Arena VC, Burger P. On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate 125I implants in ‘failed’ and ‘newly diagnosed’ glioblastoma patients: quality assurance methodology and a possible future adjuvant for therapeutic enhancement. J Neurooncol. (1995) 26:141–55. doi: 10.1007/BF01060220

193. Stea B, Rosman K, Kittelson J, Shetter A, Hamilton A, Cassidy JR. Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas: a comparative survival analysis. Int J Radiat Oncol Biol Phys. (1994) 30:591–600. doi: 10.1016/0360-3016(92)90945-E

194. Nakajima T, Roberts DW, Ryan TP, Hoopes P, Coughlin CT, Tremblay BS, et al. Pattern of response to interstitial hyperthermia and brachytherapy for malignant intracranial tumor: a CT analysis. Int J Hyperthermia. (1993) 9:491–502. doi: 10.3109/02656739300000547

195. Iacono RP, Stea B, Lulu BA, Catas T, Cassidy JR. Template-guided stereotactic implantation of malignant brain tumors for interstitial thermoradiotherapy. Stereotact Funct Neurosurg. (1992) 59:199–204. doi: 10.1119/0000098942

196. Sneed PK, Stauffer PR, Gutin PH, Phillips TL, Suen S, Weaver KA, et al. Interstitial irradiation and hyperthermia for the treatment of recurrent malignant brain tumors. Neurosurgery. (1991) 28:206–15. doi: 10.1227/00006123-199102000-00006

197. Stea B, Cetas TC, Cassidy JR, Seeger J, Shetter A, Shimm D. Interstitial thermoradiotherapy of brain tumors: preliminary results of a phase i clinical trial. Int J Radiat Oncol Biol Phys. (1990) 19:1463–71. doi: 10.1016/0360-3016(90)90359-R
208. Sneed PK, Gutin PH, Stauffer PR, Phillips TL, Prados MD, Weaver KA, et al. Thermodoraotherapy of recurrent malignant brain tumors. Int J Radiat Oncol Biol Phys. (1992) 23:853–61. doi: 10.1016/0360-3016(92)90659-6

209. Edwards DK, Stupperich TK, Baumann CK, Zumwalt CB. Volumetric interstitial hyperthermia: role of the critical care nurse. Focus Crit Care. (1991) 18:35–9

210. Salcman M, Samaras MJ. Interstitial microwave hyperthermia for brain tumors. Results of a phase-1 clinical trial. J Neurooncol. (1983) 1:225–36. doi: 10.1007/BF00165607

211. Fan M, Ascher PW, Schrottner O, Ebner F, Germann RH, Kleinert R. Interstitial 1.06 Nd:YAG laser thermotherapy for brain tumors under real-time monitoring of MRI: experimental study and phase I clinical trial. J Clin Laser Med Surg. (1992) 10:355–61. doi: 10.1089/clm.1992.10.355

212. Kahn T, Harth T, Bettag M, Schwabe B, Ulrich F, Schwarzmaier HJ, et al. Preliminary experience with the application of gadolinium-DTPA before MR imaging-guided laser-induced interstitial thermotherapy of brain tumors. J Magn Reson Imaging. (1997) 7:226–9. doi: 10.1002/jmir.1880070135

213. Borok TL, Winter A, Laing I, Paglione R, Sterzer F, Sinclair I, et al. Microwave hyperthermia radiosensitized iridium-192 for recurrent brain malignancy. Med Dosim. (1988) 13:29–36. doi: 10.1097/00005987-19890109-00010

214. Jordan A, Scholz R, Maier-Hauff K, Johannsen M, Wust P, Nadobny J, et al. A feasibility study of interstitial hyperthermia plus external beam radiotherapy in glioblastoma multiforme using the Multi Electrode Current Source (MECS) system. Int J Hyperthermia. (2004) 20:451–63. doi: 10.1080/02656730410001668357

215. Guthkelch AN, Carter LP, Cassady JR, Hynynen KH, Iacono RP, Johnson BM, et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic field hyperthermia. J Magn Magn Mater. (2001) 225:118–26. doi: 10.1016/S0304-8853(00)01239-7

216. Stalpers LJA, et al. A feasibility study of interstitial hyperthermia plus external beam radiotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. (1998) 40:287–95.

217. Bahlo J, Doppene Curto F, Rotella G. Hyperthermia in the treatment of brain tumors: clinical trials. J Neurooncol. (1992) 15:597–601. doi: 10.1007/BF00168357

218. Pontiggia P, Doppone Curto F, Rotella G. Hyperthermia in the treatment of brain metastases from lung cancer. Experience on 17 cases. Anticancer Res. (1995) 15:597–601.

219. Van der Horst A, Versteijne E, Besselink MGH, Daams JG, Bulle EB, Bijlsma M, et al. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. Int J Hyper. (2018) 34:969–79. doi: 10.1002/ijh.21126

220. Fiorentini G, Sarti D, Casadei V, Milandri C, Dentico P, Mambrini A, et al. Modulated electro-hyperthermia as palliative treatment for pancreas cancer: a prospective observational study on 106 patients. Integrative Cancer Therapies. (2019) 18:1–8. doi: 10.1177/1534754819878505

221. Volovat C, Volovat SR, Sirciparu V, Miron L. Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer - preliminary results of a prospective trial. Rom Rep Phys. (2014) 6:166–74.

222. Dani A, Varkonyi A, Magyar T, Szasz A. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. BMJ Open. (2017) 7:e013787. doi: 1136/bmjopen-2017-017387

223. Gonzalez-Cao M, Salgado E, Rodriguez J. Docetaxel (D) and gemcitabine (G) in patients with advanced pancreatic cancer: a multicenter Phase II study. Proc Am Soc Clin Oncol. (2001) 20:A2274.

224. Cozzi M, Schettino G, Tsavaris N. First-line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced pancreatic cancer: a phase I trial. J Clin Oncol. (1992) 10:355–61. doi: 10.1097/00005030-19920305-00032

225. Matsu Y, Nakagawa A, Kamiyama Y, Yamamoto K, Kubo N, Nakase Y. Selective thermocouagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas. (2000) 20:14–20. doi: 10.1097/00006676-200010000-00002

226. Pastore C, Fioranelli M, Rocca MG. Rescue therapy in patient with glioblastoma multiforme combining chemotherapy, hyperthermia, phytotherapy. J Integrative Oncol. (2017) e1199.
244. Raymond U. Clinical Results Using 8 MHz Radiofrequency Capacitive Hyperthermia and Radiotherapy for Recurrent Breast Carcinoma. Raleigh, CA: Rex Healthcare Cancer Center (2002).

245. Masunaga S, Hiraoka M, Takahashi M, Jo S, Akuta K, Nishimura Y, et al. Clinical results of thermoradiotherapy for locally advanced and/or recurrent breast cancer – comparison of results with radiotherapy alone. Int J Hyp. (1990) 6:847–97. doi: 10.3109/02656739009140945

246. Kouloulias VE, Dardoufas CE, Kouvaris JR, Gennatas CS, Polyzos AK, Gogas HJ, et al. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Cancer Res. (2002) 8:374–82.

247. Bornstein BA, Zouranjian PS, Hansen JL, Fraser SM, Gelwan LA, Teicher BA, et al. Long-term results of hyperthermic perfusion with chemotherapy in malignant pleuritis. Dpt. of Thoracic Surgery, The Center for Adult Diseases and Mi. (1993) 22:1009–14. doi: 10.1016/0360-3016(92)1445

248. Lee SY, Lee N-R. Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib. Korean. J Intern Med. (2016) 16:242. doi: 10.3904/kjm.2015.242

249. Schirrmacher V, Stücker W, Lulei M, Bihari A-S, Sprenger T. Long-term results of hyperthermic perfusion and local radiotherapy for advanced non-small cell lung cancer. Int J Radiation Oncol Biol Phys. (1992) 29:1109–14. doi: 10.1016/0360-3016(92)1445

250. Feyerabend T, Wioedemann GJ, Jager B, Vesely H, Mahlmann B, Richter E. Int J Hyperthermia. (2004) 20:252–77. doi: 10.1080/0265673031000160552

251. Raymond U. Clinical Results Using 8 MHz Radiofrequency Capacitive Hyperthermia and Radiotherapy for Recurrent Breast Carcinoma. Raleigh, CA: Rex Healthcare Cancer Center (2002).

252. Lee SY, Lee N-R. Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib. Korean. J Intern Med. (2016) 16:242. doi: 10.3904/kjm.2015.242

253. Yoshikawa T, Oyamada H, Ichikawa H, Naito Y, Ueda S, Tainaka K, et al. Regional hyperthermia combined with radiotherapy in the treatment of lung cancer. Int J Radiat Oncol Biol Phys. (1992) 22:1009–14. doi: 10.1016/0360-3016(92)90980-W

254. Kondo M, Oyamada H, Shimizu T, Tozawa T, Nishikawa M, et al. Efficacy of metabolically supported chemotherapy combined with hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Cancer Res. (2002) 7:855–60. doi: 10.1158/1078-0432.CAN-01-1148

255. Lyskieski MS, Slocum AK, Slocum A, Beradka FB, Kalamian M, et al. Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer. Cureus. (2017) 9:e1445.doi: 10.7759/cureus.

256. Kondo M, Oyamada H, Shimizu T, Tozawa T, Nishikawa M, et al. Efficacy of metabolically supported chemotherapy combined with hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Cancer Res. (2002) 7:855–60. doi: 10.1158/1078-0432.CAN-01-1148

257. Lee D-Y, Park S-J, Jung H-C, Byun ES, Haam S, Lee S-S. The Outcome of the chemotherapy and oncothermia for advanced adenocarcinoma of the lung: case reports of four patients. Adv Lung Cancer. (2015) 4:1–7. doi: 10.4236/alc.2015.41001

258. Ou J, Zhu X, Lu Y, Zhao C, Zhang H, Wang X, et al. The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small-cell lung cancer: a case report. Exp Therapeut Med. (2015) 15:1–4.

259. Lee D-Y, Park S-J, Jung H-C, Byun ES, Haam S, Lee S-S. The Outcome of the chemotherapy and oncothermia for advanced adenocarcinoma of the lung: case reports of four patients. Adv Lung Cancer. (2015) 4:1–7. doi: 10.4236/alc.2015.41001

260. Yamamoto K, Tanaka Y. Radiofrequency capacitive hyperthermia for unresectable hepatic cancers. J Gastroenterol. (2017) 32:361–6. doi: 10.1007/ BF02934494
280. Seng J, Lee HS, Han KH, Chon CY, Suh CO, Kim GE. Combined treatment of radiotherapy and hyperthermia for unresectable hepatocellular carcinoma. *Yonsei Med J.* (1994) 35:252–9. doi: 10.3349/ymj.1994.35.3.252

281. Pacella CM, Valde D, Bizzarri G, Pacella S, Brunetti M, Mariati R, et al. Percutaneous laser ablation in patients with isolated unresectable live metastases from colorectal cancer: results of a phase II study. *Acta Oncol.* (2006) 45:77–83. doi: 10.1080/02841860500438029

282. Vogl TJ, Mack MG, Blazer JO, Engelmann K, Straub R, Eichler K, et al. Liver Metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. *Radiology.* (2003) 229:457–64. doi: 10.1148/radiol.2292001239

283. Goldberg SN, Gazelle GS, Solbiati L, Livraghi T, Tanabe KK, Hahn PF, et al. Ablation of liver tumors using percutaneous RF therapy. *AJR.* (1998) 170:1023–8. doi: 10.2214/ajr.170.4.953053

284. Hager DH, Höhmann D, Gallenbeck D, Stephan M, Popa C. (1999) Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer. *Anticancer Res.* (1998) 19:3403–8.

285. Hager ED. Lebermetastasen bei kolorektalen Karzinomen. *Deutsches Zeitschrift Onkol.* (2004) 36:132–4.

286. Gadaleta-Caldarola G, Infusino S, Galisse I, Ranieri G, Vinciarelli G, Fazio V, et al. Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma. A phase II study. *Oncol Lett.* (2014) 8:1783–7. doi: 10.3892/ol.2014.2376

287. Ohguri T, Imada H, Yahara K, Kakeda S, Tomimatsu A, Kato F, et al. Effect of 8-MHz radiofrequency-capacitive regional hyperthermia with strong superficial cooling for unresectable or recurrent colorectal cancer. *Int J Hyperthermia.* (2004) 20:465–75. doi: 10.1080/026567304006717729

288. Nishimura Y, Hiraoka M, Abe M. Thermoradiotherapy for patients with locally advanced colorectal cancer. In: Matsuda T editor. *Cancer Treatment by Hyperthermia, Radiation and Drugs.* Milton: Taylor & Francis (1993). p. 78–289.

289. Nishimura Y, Hiraoka M, Akuta K, Jo S, Nagata Y, Masunaga S-I, et al. Hyperthermia combined with radiation therapy for primarily unresectable and recurrent colorectal cancer. *Int J Radiat Oncol Biol Phys.* (1992) 23:759–68. doi: 10.1016/0360-3016(92)90649-3

290. Berdov BA, Menteshashvili GZ. Thermoradiotherapy of patients with locally advanced carcinoma of the rectum. *Int J Hyperthermia.* (1990) 6:881–90. doi: 10.3109/02656739009149970

291. Hildebrandt B, Wust P, Drager J, Ludemann L, Sreevivasa G, Tullius SG, et al. Hyperthermia combined with chemotherapy and radiotherapy for patients with carcinoma of the rectum. *Dis Colon Rectum.* (1997) 40:401–6. doi: 10.1002/DPF.225838

292. Rau B, Wust P, Gellermann J, Harder C, Riess H, et al. Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters. *Int J Radiation Oncol Biol Phys.* (2000) 48:381–91. doi: 10.1016/S0360-3016(00)00650-7

293. Ohno S, Tomoda M, Tomisaki S, Kitamura K, Mori M, Maehara Y, et al. Improved Surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patients with carcinoma of the rectum. *Dis Colon Rectum.* (1994) 37:100–6. doi: 10.1002/DF225838

294. Rau B, Wust P, Gellermann J, Tilly W, Hunerbein M, Loffel J, et al. Phase II-Studie zur praoperativen radio-chemo-therapie beim lokal fortgeschrittenen rektum-karzinom. *Strahlentherapie Onkol.* (1998) 174:556–65. doi: 10.1007/BF03038292

295. Takahashi M, Fujimoto S, Kobyashi K, Mutou T, Kure M, Masaoka H, et al. Clinical outcome of intraoperative pelvic hyperthermochemoembolotherapy for patients with Dukes‘ C rectal cancer. *Int J Hyperthermia.* (1994) 10:749–54. doi: 10.3109/0265673940912368

296. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cidofovir and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol.* (2003) 21:3737–43. doi: 10.1200/JCO.2003.04.187

297. Verwaal VI, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinoa
patients with peritoneal carcinomatosis. *Ipn J Hyperthermic Oncol.* (2003) 19:195–200. doi: 10.3191/thermalmedicine.19.195

316. Nagata Y, Hiraoka M, Nishimura Y, Masunaga S, Akuta K, Li YP, et al. Clinical experiences in the thermoradiotherapy for advanced gastric cancer. *Int J Hyperthermia.* (1995) 11:501–10. doi: 10.3109/02656739509022485

317. Schepetkin IB, Evans SR, Choyke V, Usinsky S, Buras RR, Maligonov P, et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. *Surg Oncol.* (1994) 3:37–44. doi: 10.1016/0960-7404(94)90022-1

318. Fu QG, Meng FD, Shen XD, Guo RX. Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. *World J Gastroenterol.* (2002) 8:1019–22. doi: 10.3748/wjg.v8.i6.1019

319. Hamazoe R, Maeta M, Koga S. Efficacy of intraperitoneal hyperthermic chemohyperthermia in preventing peritoneal recurrence of gastric cancer. In: Matsuda T editor. *Cancer Treatment by Hyperthermia, Radiation and Drugs.* Milton: Taylor & Francis (1993). p. 328–38.

320. Mizuguchi N, Mukojima T, Itoh M, Kobayashi Y, Kato T, Uno A, et al. Two long-term survival cases of gastric carcinoma treated with hyperthermo-chemo-radiotherapy. *Ipn J Hyperthermic Oncol.* (2002) 18:93–8. doi: 10.3191/thermalmedicine.18.93

321. Nishimura Y, Hiraoka M, Jo S, Akuta K, Nagata Y, Masunaga S, et al. Radiofrequency (RF) capacitive hyperthermia combined with radiotherapy in the treatment of abdominal and pelvic deepseated tumors. *Radiothe Oncol.* (1989) 16:139–49. doi: 10.3109/01678140(89)90031-5

322. Hiraoka M. Thermoradiotherapy for upper abdominal tumors. In: Seegenschmiedt MH, et al. editors. *Thermoradiotherapy and Thermochemotherapy.* (Vol. 2). Berlin: Springer Verlag (1996). doi: 10.1007/978-3-642-60938-1_7

323. Elias D, Sideris L, Pocard M, Ede C, Hassuona DB, Ducreux M, et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. *Ann Oncol.* (2004) 15:781–5. doi: 10.1093/annonc/mdh186

324. Elias D, Bonnay M, Puizzolou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. *Ann Oncol.* (2002) 13:267–72. doi: 10.1093/annonc/mdf019

325. Elias D, Raynard B, Farkhondeh F, Goere D, Rouquie D, Ciuchendea R, et al. A phase II trial testing the thermal dose parameter CEM43 of surgery and radio-hyperthermo-chemotherapy for patients with soft tissue sarcomas. In: Matsuda T editor. *Cancer Treatment by Hyperthermia, Radiation and Drugs.* London: Taylor & Francis (1993). p. 270–7.

326. Masunaga SI, Hiraoka M, Akuta K, Nishimura Y, Yasushi N, Shiken J, et al. Non-randomized trials of thermoradiotherapy versus radiotherapy for preoperative treatment of invasive urinary bladder cancer. *J Isp Soc Ther Radiol Oncol.* (1993) 2:313–20.

327. Moskovitz B, Meyer G, Kravtsov A, Gross M, Kastin A, Biton K, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. *Ann Oncol.* (2005) 16:585–9. doi: 10.1093/annonc/mdi124

328. Colombo R, Salania A, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). *BJU Int.* (2011) 107:912–8. doi: 10.1111/j.1464-410X.2010.09654.x

329. Hiraoka M, Nishimura Y, Nagata Y, Mitsumori M, Okuno Y, Li PY, et al. Clinical results of thermoradiotherapy for soft tissue tumors: basic considerations and results. *Int J Hyperthermia.* (1989) 16:139–49. doi: 10.3109/02656738909022472

330. Egawa S, Tsukiyama I, Kajuya Y. Clinical results of hyperthermia combined with radiation or chemotherapy for soft-tissue sarcomas. In: Matsuda T editor. *Cancer Treatment by Hyperthermia, Radiation and Drugs.* Milton: Taylor & Francis (1993). p. 290–9.

331. Rossi CR, Foleto M, Filippo FD, Vaglini M, Anza M, Azzarelli A, et al. Soft Tissue Limb Sarcomas. *Cancer.* (1999) 86:1742–9. doi: 10.1002/(SICI)1097-0248(19991010)86:9<1742::AID-CNCR16>3.0.CO;2-G

332. Otsuka T, Yonezawa M, Kamiyama F, Matsuhita Y, Mitsu N. Results of surgery and radio-hyperthermo-chemotherapy for patients with soft tissue sarcoma. *Int J Clin Oncol.* (2001) 6:223–8. doi: 10.1007/PL00012114

333. Prosnitz LR, Maguire P, Anderson JM, Scully SP, Harrelson JM, Jones EL, et al. The Treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. *Int J Radiation Oncol Biol Phys.* (1995) 39:91–7. doi: 10.1016/0360-3016(95)00272-2

334. Maguire PD, Samulski TV, Prosnitz LR, Jones EL, Rosner GL, Powers B, et al. A phase II trial testing the thermal dose parameter CEM43×T90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy. *Int J Hyperthermia.* (2001) 17:283–90. doi: 10.1080/02656730110039449

335. Rossi CR, Deraco M, Simone MD, Mocellin S, Piliati P, Foleto M, et al. Hyperthermic intraperitoneal Intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. *Cancer.* (2004) 100:1943–50. doi: 10.1002/cncr.20192

336. Wiedemann GJ, Robins HI, Gutsche S, Mzentel M, Deeken M, Katschinski DM, et al. Ifofosamide, carboplatin and etoposide (ICE) combined with 41.8
degree C whole body hyperthermia in patients with refractory sarcoma. Eur J Cancer. (1996) 32A:888–92. doi: 10.1053/0959-8409(95)00622-2

351. Wiedemann GJ, d'Oleire F, Knop E, Eleftheriadis S, Bucsky PP, Feddersen S, et al. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant tertoma. J Cancer Res. (1996) 8:1818–29. doi: 10.1007/BF01613220

352. Wiedemann GJ, Robins HI, Katschinski DM, Mentzel D, d'Oleire F, Kutz M, et al. Systemic hyperthermia and ICE chemotherapy for sarcoma patients: rationale and clinical status. Anticancer Res. (1997) 17:2899–902.

353. Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II trial. J Clin Oncol. (1990) 8:1818–29. doi: 10.1007/BF01613220

354. Issels RD, Abdel-Rahman S, Falk MH. Initial response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. (2002) 20:3156–64. doi: 10.1200/JCO.2002.07.146

355. Issels RD, Mittemüller J, Gerl A, Simon W, Ortsmaier A, Denzlinger C, et al. Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. J Cancer Res Clin Oncol. (1991) 4:541–7. doi: 10.1007/BF01613220

356. Issels RD, Bosse D, Abdel-Rahman S, Starck M, Panzer M, Steigler H, et al. Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study. Cancer Chemother Pharmacol. (1993) 31:S233–7.

357. Wendtner CM, Abdel-Rahman S, Baumert J, Lindner LH, Baur A, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. (2002) 20:3156–64. doi: 10.1200/JCO.2002.07.146

358. Wendtner CM, Abdel-Rahman S, Baumert J, Falk MH, Krych M, Santl M, et al. Treatment of primary, recurrent or inadequately resected high-risk soft tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer. (2001) 37:1609–16. doi: 10.1053/s0959-8409(01)00191-5

359. Issels RD, Abdel-Rahman S, Falk MH. Initial response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) in high-risk soft tissue sarcomas (HR-STS) of adults and its correlation to survival parameters. Eur J Cancer. (1999) 35:266. doi: 10.1053/0959-8409(99)81481-6

360. Issels RD, Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA Jr., et al. Systemic hyperthermia and ICE chemotherapy for sarcoma patients: confirmation of thermal dose as a predictor of local control in patients with locally advanced sarcomas. Int J Hyperthermia. (1990) 6:3435–9.

361. Balckburn LV, Galofero SS, Corry PM, Lee YJ. Adenoviral-mediated transfer of heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. (1998) 58:1358–62.

362. Huang Q, Hu JK, Zhang L, Braun R, Lanten J, Little JB, et al. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res. (2000) 60:3435–9.

363. Verushimali A, Shani A, Fishelovitz Y, Arielly J, Singer D, Levy E, et al. Local microwave hyperthermia in the treatment of carcinoma of the prostate. Oncology. (1986) 43:299–305. doi: 10.1159/000226387

364. Piantelli M, Tatone D, Castrilli G, Savini F, Mazzaglio N, Larocca LM, et al. Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. Melanoma Res. (2001) 11:469–76. doi: 10.1097/00000390-200110000-00005

365. Olesen JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA Jr., et al. Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol. (1988) 11:368–80. doi: 10.1097/00000421-198806000-00013

366. Henderson BW, Waldow SM, Potter WR, Dougherty TJ. Interaction of photodynamic therapy and hyperthermia: tumour response and cell survival studies after treatment of mice in vivo. Cancer Res. (1985) 45:6071–7.

367. Lohr F, Hu K, Huang Q, Zhang L, Samulski TV, Dewhirst MW, et al. Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys. (2000) 48:1513–8. doi: 10.1016/S0360-3016(00)00788-4

368. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. (2009) 10:550–8.

369. Vertrees RA, Jordan JM, Zwischenberger JB. Hyperthermia and chemotherapy: the science. In: Halem CW, Edwards RP editors. Current Clinical Oncology, Intraoperative Cancer Therapy. Totowa: Humana Press. (2008).

370. Van Rhoon G. Presentation on ESHO Conference, as President. (2014).

371. Kok HP, Navarro F, Strigari L, Cavagnaro M, Crezee J. Locoregional hyperthermia of deep-seated tumours applied with capacitive and radiative systems: a simulation study. Int J Hyperther. (2018) 34:714–30. doi: 10.1080/02656736.2018.1448119

372. Kroesen M, Mulder HT, van Holtehe JML, Aangenemb AA, Mens JWM, et al. Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. Radiother Oncol. (2019) 140:150–80. doi: 10.1016/j.radonc.2019.06.021

373. Crezee H, Kok HP, Oei AL, Franken NAP, Stalers LJ. The impact of the time interval between radiation and hyperthermia on clinical outcome in patients with locally advanced cervical cancer. Front Oncol. (2019) 9:40–2. doi: 10.3389/fonc.2019.00412

374. Kroesen M, Mulder HT, van Rhoon GC, Francenka M. Commentary: the impact of the time interval between radiation and hyperthermia on clinical outcome in patients with locally advanced cervical cancer. Front Oncol. (2019) 9:1387. doi: 10.3389/fonc.2019.01387

375. Lee S-Y, Kim J-H, Han Y-H, Cho D-H. The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma. Int J Hyperthermia. (2018) 34:1–24. doi: 10.1080/02656736.2018.1423709

376. Harima Y, Ohguri T, Imada H, Sakurai H, Ohno T, Hiraki Y, et al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer. Jpn J Hyp. (2016) 32:801–8. doi: 10.1007/s02656736.2016.1213430

377. Szasz A, Arkosy P, Arroyo EE, Bakacs T, Balogh A, Barich J, et al. Guidelines for local hyperthermia treatment in oncology. 1 ed. In: Szasz A editor. Challenges and Solutions of Oncologic Hyperthermia. Cambridge Scholars (2020), p. 32–72.

378. Jones E, Thrall D, Dewhirst MW, Vujaskovic Z. Prospective thermal dosimetry: the key to hyperthermia’s future. Int J Hyperthermia. (2006) 22:247–53. doi: 10.1080/02656736.2006.756702

379. Dewhirst MW, Viglianti BL, Lora-Michels M, Hanson M, Hoopes PJ. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia. (2003) 19:267–94. doi: 10.1080/026567301019006
386. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. *Int J Radiat Oncol Biol Phys*. (1984) 10:787–800. doi: 10.1016/0360-3016(84)90379-1

387. Maquire PD, Samulski TV, Prosnitz LR, Jones EL, Rosner GL, Powers B, et al. Phase II trial testing the thermal dose parameter CEM43 degrees C as a predictor of response in soft tissue sarcomas treated with pre-operative radiotherapy. *Int J Hyperthermia*. (2001) 17:283–90. doi: 10.1080/0265673011039449

388. de Bruijne M, van der Holt B, van Rhoon GC, van der Zee J. Evaluation of CEM43/CT90 thermal dose in superficial hyperthermia; a retrospective analysis. *Strahlenther Onkol (Radiother Oncol)*. (2010) 186:436–43. doi: 10.1007/s00066-010-1146-x

389. Fatehi D, van der Zee J, van der Wal E, van Wieringern WN, van der Zee J, de Bruijne M, van der Holt B, van Rhoon GC, van der Zee J, et al. Temperature data analysis for 22 patients with advanced cervical carcinoma treated in Rotterdam using radiotherapy, hyperthermia and chemotherapy; a reference point is needed. *Int J Hyperthermia*. (2006) 22:353–63. doi: 10.1080/02656700600715796

390. Song CW. Effect of Local hyperthermia on blood flow and microenvironment: a review. *Cancer Res*. (1984) 44(Suppl. 10):4721–30.

391. Shen R-N, Lu L, Young P, Shidnia H, Hornback NB, Broxmeyer HE. Influence of elevated temperature on natural killer cell activity, lymphokine-activated killer cell activity and lectin-dependent cytotoxicity of human umbilical cord blood and adult blood cells. *Int J Radiation Oncology Biol Phys.* (1994) 29:821–6. doi: 10.1016/S0360-3016(94)80057-1

392. Hietanen T, Kapanen M, Kellokumpu-Lehtinen PL. Restoring natural killer cell cytotoxicity after hyperthermia alone or combined with radiotherapy. *Anticancer Res*. (2016) 36:555–63. doi: 10.21873/anticanres.11429

393. Lee et al. What Is on the Horizon for 2020?

394. Sulyok I, Fleischmann E, Stift A, Roth G, Lebherz-Eichinger D, Kasper Dieing A, Ahlers O, Hildebrandt B, Kerner T, Tamm I, Possinger K, et al. The influence of elevated temperature on natural killer cell activity, lymphokine-activated killer cell activity and lectin-dependent cytotoxicity of human umbilical cord blood and adult blood cells. *Int J Radiation Oncology Biol Phys.* (1994) 29:821–6. doi: 10.1016/S0360-3016(94)80057-1

395. Yang K-L, Huang C-C, Chi M-S, Chiang H-C, Wang Y-S, Andocs G, et al. In vitro comparison of conventional hyperthermia and modulated electro-hyperthermia. *Oncotarget*. (2016) 7:84082–92. doi: 10.18632/oncotarget.11444

396. Andocs G, Renner H, Balogh L, Fonyad L, Jakab C, Szasz A. Strong synergy of heat and modulated electro- magnetic field in tumor cell killing. Study of HT29 xenograft tumors in a nude mice model. *Strahlenther Onkol*. (2009) 185:120–6. doi: 10.1007/s00066-009-1903-1

397. Y. Andocs G. Preclinical Investigation on The Biological Effects of Modulated Electro-Hyperthermia. *Graduate School of Medicine and Pharmaceutical Sciences*. (2015). Ph.D. thesis, University of Toyama, Toyama.

398. Meggyeshazi N, Andocs G, Krenacs T. Programmed cell death induced by modulated electro-hyperthermia. *Int J Hyperthermia*. (2015) 31:187835.

399. Meggyeshazi N, Studies on Modulated Electrotheraphy Induced Tumor Cell Death in a Colorectal Carcinoma Model. *Pathological Sciences* 2015:187289.

400. Meggyeshazi N, Andocs G, Krenacs T. Programmed cell death induced by modulated electro-hyperthermia. *Int J Hyperthermia*. (2016) 32:187289.

401. Song CW. Effect of Local hyperthermia on blood flow and microenvironment: a review. *Cancer Res*. (1984) 44(Suppl. 10):4721–30.

402. Shoolery, D. The presence of gold nanoparticles in cells associated with the cell-killing effect of modulated electro-hyperthermia. *Acupuncture and Electro-Therapeutics*.* Res Int J*. (2013) 7:216–29. doi: 10.4236/ojbiphy.2017.74016

403. Heegy G, Szasz O, Szasz A. Oncotherapy: a new paradigm and promising method in cancer therapies. *Acupuncture and Electro-Therapeutics*.* Res Int J*. (2013) 38:161–97. doi: 10.4236/ojbiphy.2016.63007

404. Vincze Gy, Zigeti Gy, Andocs G, Szasz A. Nanoheating without artificial nanoparticles. *Biomed. Med.* (2015) 7:249.

405. Staunton JR, Agus DB, Alexander JF, Arap W, Ashli S, Aslan JE, et al. The physical sciences - oncology centers network. A *Phys Sci Newt Character Non Tumorig Metast Sci Rep*. (2008) 3:1449.

406. Andocs G, Rehman MU, Zhao QL, Papp E, Kondo T, Szasz A. Nanoheating without Artificial Nanoparticles Part II. Experimental support of the nanoheating concept of the modulated electro-hyperthermia method, using U937 cell suspension model. *Biomed. Med.* (2015) 7:1–9. doi: 10.4172/0974-8369.1000247

407. Andocs G, Rehman MU, Zhao Q-L, Tabuchi Y, Kamamori M, Kondo T. Comparison of biological effects of modulated electro-hyperthermia and conventional heat treatment in human lymphoma U937 cell. *Cell Death Discovery (Nature Publishing Group)*. (2016) 2:16039. doi: 10.1038/cddiscovery.2016.39

408. Szasz A. Oncotherapy: Complex Therapy by EM and Fractal Physiology, XXXIth URSI General Assembly and Scientific Symposium (URSI GASS), IEEE Xplore 20 October (2014), doi: 10.1109/URSIGASS.2014.693100 (2020). Available online at: https://ieeexplore.ieee.org/document/693100 (assessed March 6, 2020).

409. Cha J, Jeon T-W, Lee C-G, Oh ST, Yang H-B, Choi J-I, et al. Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis. *Int J Hyperthermia*. (2015) 31:784–92. doi: 10.3109/02656736.2015.1069411

410. Meggyeshazi N, Andocs G, Spisak S. Modulated electrohyperthermia causes caspase independent programmed cell death in HT29 colon cancer xenografts. *Virchows Arch*. (2013) 463:329.

411. Andocs G, Renner H, Balogh L, Fonyad L, Jakab C, Szasz A. Strong synergy of heat and modulated electro- magnetic field in tumor cell killing. *Strahlenther Onkol*. (2009) 185:120–6. doi: 10.1007/s00066-009-1903-1
Conflict of Interest: AS is Chief Scientific Officer of Oncotherm Kft.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Lee, Fiorentini, Seasz, Szigeti, Seasz and Minnaar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

[424] Qin W, Akutsu Y, Andocs G, Suganami A, Hu X, Yusup G, et al. Modulated electro-hyperthermia enhances dendritic cell therapy through an abscopal effect in mice. Oncol Rep. (2014) 32:2373–9. doi: 10.3892/or.2014.3500

[425] Tsang Y-W, Huang C-C, Yang K-L, Chi M-S, Chiang H-C, Wang Y-S, et al. Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy. BMC Cancer. (2015) 15:708. doi: 10.1186/s12885-015-1690-2

[426] Wust P, Ghadjar P, Nadobny J, Beck M, Kaul D, Winter L, et al. Physical analysis of temperature-dependent effects of amplitude-modulated electromagnetic hyperthermia. Int J Hyperthermia. (2019) 36:1245–53. doi: 10.1080/02656736.2019.1692376

in colorectal cancer allografts. J Cancer. (2018) 9:41–53. doi: 10.7150/jca.21520